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ABSTRACT 
Vascular endothelial growth factor C (VEGFC) promotes tumor progression in several turn or 
types, mainly through the stimulation of lymphangiogenesis and lymphatic metastasis. 
The expression and biological significance of the VEGFC/VEGFR3 pathway in ovarian 
cancer growth and dissemination has been investigated in this thesis using ovarian carcinoma 
cell1ines and tumor animal models. 
In patient-derived ovarian carcinoma xenografts (HOC), high levels of soluble VEGFC in 
ascites and serum were detected, in association with disease progression and turn or burden. 
Peak VEGFC expression preceded para-aortic lymph node infiltration by HOC8 neoplastic 
cells. Histological detection of tumor cells in blood and lymphatic vessels indicated both 
hematogenous and lymphatic dissemination. 
VEGFC was over-expressed in the VEGFR3-positive and luciferase-expressing lA9 and 
IGROVl ovarian cancer cells. In vitro, VEGFC released by the expressing tumor cells 
stimulated tumor cell migration in an autocrine manner. In vivo, over-expression of VEGFC 
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promoted IGROVl dissemination after orthotopic intraovarian transplantation in nude mice. 
VEGFC released in serum of mice correlated with tumor burden and metastasis. 
Cediranib, a small molecule receptor tyrosine kinase inhibitor of VEGFRl-3 and c-Kit, 
inhibited in vivo metastasis ofVEGFC-overexpressing IGROVl and in vitro autocrine effects 
on tumor cell migration; cediranib improved the survival of mice bearing the four HOC 
xenografts analyzed. The therapeutic benefit was proportional to soluble VEGFC levels in 
serum and ascites and to VEGFR3 expression by tumor cells. 
Different schedules of cediranib were tested on HOC8 xenograft. The survival benefit of 
cediranib in maintenance regimen (14 weeks) was superior to 3-weeks treatment. A 
significant prolongation of mice survival was observed in mice treated with advanced tumor. 
Treatment benefits were improved combining cediranib with chemotherapy (paclitaxel plus 
cisplatin). 
These findings suggest that the VEGFCNEGFR3 pathway acts as an enhancer of ovarian 
cancer progression through autocrine and paracrine mechanisms, hence offering a potential 
target for therapy. 
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Chapter 1 
1.1 Epithelial ovarian cancer 
1.1.1 Epidemiology 
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Epithelial ovarian cancer (EOC) is the fifth highest cancer-related cause of death in women in 
Western countries (Siegel, Naishadham et al. 2013). In 2008, it was estimated that 225500 
women were diagnosed with ovarian cancer and the estimated deaths worldwide were 
140200. These values make ovarian cancer the eighth most common type of cancer 
worldwide, and the seventh most common cause of death related to cancer among women 
(Jemal, Bray et al. 2011). Ovarian cancer has the highest mortality rate of any gynecological 
malignanc>:,jn developed regions of the world and is second to cervical cancer in developing 
regions (Jemal, Bray et al. 2011). 
The high mortality of ovarian cancer is primary due to difficulties in diagnosing early stage 
disease indeed most patients (about 75%) present with advanced stage tumors (Karst and 
Drapkin 2010). Stage at diagnosis has a profound influence on the overall prognosis and 
survival of the patient, with only a 27% of the women diagnosed with distant disease 
surviving at least 5 years post-diagnoses (Lowe, Chia et al. 2013). 
Unfortunately, the current screening modalities are not effective for detecting ovarian cancer 
in asymptomatic patients. Typical symptoms are vague and are often confused with 
gastrointestinal diseases, and in many cases symptoms may not even present until the tumor 
has reached an advanced stage (Karst and Drapkin 2010). 
1.1.2 Risk/actors 
The most important risk factor is strong family history of ovarian or breast cancer, although 
an identifiable genetic predisposition, such as Breast Cancer Type 1 and 2 Susceptibility 
Proteins (BReA IIBRCA2) tumor suppressor gene mutations, is present only in 10-15% of 
patients (Bast, Hennessy et al. 2009). Early menarche, late menopause, nulliparity, and 
2 
Chapter 1 Alessandra Agnese Decio 
increasing age are also associated with increased risk, whereas oral contraceptive use, 
pregnancy, breast-feeding, and tubal ligation are associated with reduced risk (Edmondson 
and Monaghan 2001). These epidemiological data could be explained by the incessant 
ovulation hypothesis that postulates that repetitive wounding of the ovarian surface epithelium 
and cell proliferation in postovulatory repair result in a stepwise accumulation of genomic 
abnormalities. Ovarian epithelial inclusion cysts occur as a result and might increase the risk 
of carcinogenesis by entrapping cells in a growth factor rich environment (Fathalla 1971). 
Furthermore, surges of pituitary gonadotropins at ovulation and persistent high concentrations 
after menopause stimulate surface epithelium cells, resulting in accumulation of genetic 
changes and carcinogenesis (Cramer and Welch 1983). Inflammation and changes in redox 
potential might have a role in the setting of ovulation and surface-epithelium repair and might 
account for the increased risk of epithelial ovarian cancer associated with talc or asbestos 
exposure, endometriosis, pelvic inflammatory disease and mumps (Cramer, Hutchison et al. 
1983). 
1.1.3 Pathology 
The term "ovarian cancer" refers not to a single disease, but to a heterogeneous group of 
malignancies affecting the ovary. In general, ovarian tumors may develop from one of three 
cell types: epithelial cells, sex cord-stromal cells (including granulosa, theca, and hilus cells), 
or germ cells (oocytes). Although about 40% of all ovarian tumors are non-epithelial in 
origin, such lesions rarely progress to a malignant state and account for 10% of ovarian 
cancers (Chen, Ruiz et at. 2003). 
Epithelial ovarian carcinomas are themselves a heterogeneous group of neoplasms that exhibit 
a wide range of tumor morphologies, clinical manifestations, underlying genetic alterations. 
According to the International Federation of Gynecology and Obstetrics (FIOO) 
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classification, epithelial ovarian cancers are classified by diagnosis of malignancy in 4 stages 
on the basis of the extension of the tumor beyond the ovary (Benedet, Bender et al. 2000): 
stage I indicates confinement to the ovary; 
stage 11 tumors extend beyond the ovary to adjacent pelvic structures such as the 
fallopian tube or uterus; 
stage III indicates metastasis to the peritoneum and/or regional lymph nodes; 
stage IV tumors have metastasized beyond the peritoneum to distant sites. 
Additionally, tumors are classified by histopathological grade (I-III) and appearance into 
serous, endometrioid, mucinous and less commonly, clear cell, transitional cell, squamous 
cell, mixed epithelial, and undifferentiated subtypes (Tavassoli and Devilee 2003). Within 
each subtype, tumors are further described as either benign, malignant, or borderline and, 
depending upon tumor subtype, classified as low- or high-grade. Borderline tumors are 
considered to have low malignant potential andlor indolent behavior. There are major 
differences in incidence, tumor behavior (Iow versus high malignant potential), and clinical 
outcome between each histologic subtype. 
The traditional view of ovarian cancer asserts that all tumor subtypes share a common origin 
in ovarian surface epithelium, that is a flat-to-cuboidallayer of uncommitted mesothelial cells 
covering the exterior surface of the ovary. Subsequent metaplastic changes lead to the 
development of the different cell types. Recent studies have provided evidences that what 
have been traditionally thought to be primary ovarian tumors actually originate in other pelvic 
organs and involve the ovary secondarily. Thus, it has been suggested that serous carcinoma 
arise from the implantation of epithelium from the fallopian tube, while endometriosis is 
considered the precursor of endometrioid and clear cell tumors (Kurman and Shih le 20 I 0). 
Consequently, over the last several years, a dualistic model for the pathogenesis of ovarian 
carcinoma has emerged. In this model, epithelial tumors are divided into two groups, types I 
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and II (Kurman and Shih le 2010), based on their distinctive clinicopathologic and molecular 
genetic features. It also links specific histologic types with their putative precursor lesions. 
Type I tumors comprise low-grade serous carcinomas, low-grade endometrioid, clear cell, and 
mucinous carcinomas, which develop in a stepwise fashion from well-established precursor 
lesions, such as borderline tumors and endometriosis. 
They typically present as large masses that are confined to one ovary (stage la), are indolent, 
and have a good prognosis. The type I tumors are relatively genetically stable and typically 
display a variety of somatic sequence mutations that include Kirsten rat sarcoma viral 
oncogene homolog (KRAS), v-raf murine sarcoma viral oncogene homo log B (BRAF), 
Phosphatase and tensin homolog (PTEN), Phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA), Catenin (cadherin-associated protein), beta I (CTNNB 1), 
AT rich interactive domain lA (SWI-like) (ARID lA), and Protein phosphatase 2, regulatory 
subunit A, alpha (PPP2RIA) but very rarely Tumor protein p53 (TP53) (Shih le and Kurman 
2004; Jones, Wang et al. 2010). 
In contrast, type 11 tumors comprise high-grade serous carcinoma, high-grade endometrioid 
carcinoma, malignant mixed mesodermal turnors (carcinosarcomas), and undifferentiated 
carcinomas, which present in advanced stage (stages II-IV) in more than 75% of cases; they 
grow rapidly and are highly aggressive. Type 11 tumors, of which high-grade serous 
carcinoma is the prototypic type, are chromosomally highly unstable and harbor TP53 
mutations in more than 95% of cases (Ahmed, Etemadmoghadam et af. 2010) and they rarely 
display the mutations found in the type I tumors. BRCA inactivation, either by mutation or 
inactivation of expression of BRCA and its downstream genes via promoter methylation, 
occurs in up to 40% to 50% of high-grade serous carcinoma (Senturk, Cohen et af. 2010). 
BRCA inactivation has not been reported in the type I tumors. 
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1.2 Lymph node metastasis and lymphatic dissemination 
Ovarian cancer metastasizes either by direct extension from the ovarianlfallopian tumor to 
neighboring organs (bladder/colon) or by detachment of cancer cells from the primary tumor. 
Exfoliated tumor cells are transported throughout the peritoneum by ascites and disseminate 
within the abdominal cavity (Lengyel 20 I 0). Cancer cells do not immediately adhere to a 
peritoneal surface, but move with ascites vehicle to distant sites by physical forces such as 
fluid hydrodynamics and gravity. In contrast, in the absence of ascites, cancer cells are 
restricted in motion and implant near the primary site (Carmignani, Sugarbaker et af. 2003). 
Malignant cells implant anywhere in the peritoneal cavity but likely along the preferential 
flow and site of peritoneal fluid stasis, such as in the pelvis, near the ileocecal valve region 
and along the right paracolic gutter. Frequent invasion of the diaphragm and greater omentum 
may be explained by the presence of lymphatic lacunae on the peritoneal surface of the 
diaphragm and lymphoid tissue present on the greater omentum. These tissues absorb 
peritoneal fluid and thereby draw cancer cells to their surface (Feki, Berardi et af. 2009). 
Besides the dissemination through peritoneal fluid, lymphatic invasion and hematogenous 
dissemination are common in ovarian cancer (Feki, Berardi et al. 2009). 
In particular, lymphangiogenesis, the formation of new lymphatic vessels may play a role in 
lymphatic dissemination (Skobe, Hawighorst et af. 200 I; Stacker, Caesar et al. 2001; Beasley, 
Prevo et al. 2002). 
Physiological lymphangiogenesis is primarily a developmental process and is uncommon in 
adult tissues. However, new lymphatic vessels form in adult tissues during follicle maturation 
and wound healing (Paavonen, Puolakkainen et al. 2000; Saaristo, Tammela et af. 2006). 
Lymphatic vessel growth is also associated with pathological conditions such as turn or 
metastasis and inflammation in different types of tumors (Karpanen and Alitalo 2008). 
Animal models suggest that Iymphangiogenesis occurs in malignancy and that inhibiting this 
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process can halt the spread to lymphatics (Makinen, J ussila et af. 2001; Mandriota, J ussila et 
al. 2001; Shimizu, Kubo et al. 2004). However, tumour cell invasion of pre-existing 
lymphatics at the tumour margin can also occur (Jackson, Prevo et al. 2001; Pepper 2001). 
Thus, regional lymph nodes are the first site to develop metastases, either draining via pre-
existing afferent lymphatic vessels or via newly formed lymphatic capillaries (Skobe, 
Hawighorst et al. 2001; Stacker, Achen et af. 2002). 
In particular, the incidence of positive lymph nodes in patients with early stage ovarian cancer 
is 5.1-15% (Cass, Li et al. 2001), but lymphatic dissemination to the pelvic and para-aortic 
lymph nodes is common in an advanced-stage disease (50% of patients have positive lymph 
nodes) (Plentl and Friedman 1971; Chen and Lee 1983; Burghardt, Pickel et af. 1986). For 
this reason, the lymph nodes status is currently the most valuable prognostic factor for 
patients with early-stage ovarian tumors confined to the ovary (Maggioni, Benedetti Panici et 
al. 2006; Yavuzcan, Baloglu et al. 2009), as tumor metastasis to regional (sentinel) lymph 
nodes often represents the first step of tumor dissemination and serves as a major prognostic 
indicator for the progression of human cancers (Tobler and Detmar 2006). 
Over the past 2 decades, members of the Vascular Endothelial Growth Factor (VEGF) family 
have been shown to be essential regulators of lymphangiogenesis (Figure 1.1) (Lohela, Bry et 
al. 2009). In particular, the main lymphangiogenic factor in both physiological and 
pathological settings is VEGFC (Joukov, Pajusola et af. 1996; Karkkainen, Haiko et al. 2004). 
VEGFD has similar properties, but its role as an endogenous regulator of lymphangiogenesis 
is less clear (Achen, McColl et al. 2005). 
Although VEGFC and VEGFD, acting through VEGFR3 (Flt4), the first lymphatic-specific 
growth factor receptor identified (Kaipainen, Korhonen et af. 1995), and, to some extent, 
VEGFR2, are the key growth factors that can directly stimulate the lymphatic endothelium, 
other growth factors have been implicated in lymphangiogenesis. Both VEGF A and VEGFE 
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have been shown to promote the growth of lymphatic vessels, which express low levels of 
VEGFR2 (Nagy, Vasile et al. 2002; Saaristo, Veikkola et al. 2002; Wirzenius, Tammela et al. 
2007). In addition, fibroblast growth factor-2, insulin-like growth factor-l and -2, hepatocyte 
growth factor, lymphotoxin, and platelet-derived growth factor-B have been shown to induce 
Iymphangiogenesis in experimental models (Cueni and Detmar 2006; Mounzer, Svendsen et 
al. 2010). 
The Angiopoietin I (Angl) receptor Tyrosine kinase with immunoglobulin-like and EGF-like 
domain 2 (Tie2) is expressed in cultured lymphatic endothelial cells (LECs) and in lymphatic 
vessels in vivo (Kriehuber, Breiteneder-Geleff et al. 200 I; Makinen, Veikkola et al. 2001; 
Morisada, Oike et al. 2005; Tammela, Saaristo et al. 2005; Kim, Cho et al. 2007). 
Analysis of gene-targeted mice has shown that Angiopoietin 2 (Ang2) is essential for the 
proper patterning of lymphatic vessels, whereas Ang I is able to rescue the lymphatic 
phenotype, suggesting that both ligands act as receptor agonists in LECs (Morisada, Oike et 
al. 2005; Tammela, Saaristo et al. 2005; Kim, Cho et al. 2007). 
1.3 Vascular Endothelial Growth Factor C (VEGFC) 
The expression of several growth factors and their cognate receptors determines the 
aggressive phenotype of cancer cells and regulates tumor invasion and metastasis (A vraham, 
Park et al. 2000). In particular, the expression of vascular endothelial growth factor C 
(VEGFC), the main promoter of lymphatic vessel formation, is considered essential for the 
spread of tumor cells to lymph nodes (Skobe, Hawighorst et al. 200 I; Stacker, Achen et al. 
2002). 
VEGFC is a member of the VEGF family of vascular growth factors, which comprises 
VEGFA, B, C, and D and Orf virus VEGFs (or VEGFE) (Figure 1.2) (Eriksson and Alitalo 
1999; Ferrara 1999). 
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The secreted glycoprotein VEGFC was first isolated as the cognate ligand of VEGFR3 by 
Alitalo and co-workers (Joukov, Pajusola et al. 1996) and was associated with the broader 
VEGF family of receptors and gro\Vth factors (Achen, Clauss et al. 1995; Achen, Gad et al. 
1997; Achen and Stacker 1998; Ferrara and Alitalo 1999), that play a major role in the gro\Vth 
and development of blood vessels. VEGFC subsequently became the first defined 
Iymphangiogenic growth factor (Jeltsch, Kaipainen et al. 1997). 
1.3.1 VEGFC - Gene structure 
VEGFC is comprised of over 40 kilobase pairs of genomic DNA and its gene structure 
consists of seven exons, which all contain coding sequences. The exon structure of VEGFC 
resembles that of the other VEGF family members, particularly in exons 3 and 4 encoding the 
core growth factor domain, which contains the eight cysteine residues (Figure 1.3) and the 
signature sequence PXCVXXXRCXGCC conserved in all Platelet Derived Growth Factor 
(PDGF)NEGF family members. Analysis of the distribution of the various motifs encoded by 
human VEGFC gene shows that the signal sequence and the first residues of the N-terminal 
propeptide are encoded by exon 1 (Figure 1.3). The second exon encodes the carboxyl-
terminal part of the N-terminal peptide and the amino terminus of the VEGF homology 
domain. The region encoding the 21-kDa form of VEGFC (Joukov, Sorsa et al. 1997) after 
proteolytic processing of both the Nand C termini is marked black in Figure 1.3. Exon 4 
encodes the sequence for the major proteolytic cleavage site of the VEGFC precursor between 
the VEGF homology domain and the C-terminal propeptide (Joukov, Sorsa et al. 1997). 
Notably, in contrast with the other VEGF genes, exon 4 contains a 24-amino acid C-terminal 
extension after the last cysteine residues conserved in the VEGF homology domain. The most 
variable parts of these genes are the regions encoded by the sixth and seventh exons, which 
are alternatively spliced in all other members except VEGFC. A short fifth exon is present in 
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all splicing variants of the other genes, but VEGFC appears to lack such an exon. Exons 5 and 
7 encode cysteine-rich motifs of the type C6CIOCRC, and exon 6 encodes additional 
C IOCXCXC motifs typical of a silk protein (Tischer, Mitchell et al. 1991). A putative 
alternatively spliced rare RNA form lacking exon 4 was identified in human fibrosarcoma 
cells (Chilov, Kukk et al. 1997), and a major transcription start site was located in the human 
VEGFC gene 523 base pairs upstream of the translation initiation codon (Chilov, Kukk et al. 
1997). The upstream promoter sequences contain conserved putative binding sites for 
Specificity Protein 1 (Sp-l) (Pugh and Tjian 1990), Activating Protein 2 (AP-2) (Imagawa, 
Chiu et al. 1987; Mitchell, Wang et al. 1987; Gille, Swerlick et al. 1997), and Nuclear factor 
kappa light polypeptide gene enhancer in B cells (NF-kB) (Lenardo and Baltimore 1989; 
Baeuerle and Baltimore 1996) transcription factors but no Thymine Adenine Thymine 
Adenine (TA TA) box. 
1.3.2 VEGFC - Protein 
VEGFC is synthesized as a proprotein (Figures 1.4 and 1.5) that is 30% identical in amino 
acid sequence to VEGF165 (Joukov, PajusoJa et al. 1996; Joukov, Sorsa et al. 1997). Nascent 
VEGFC consists of a signal sequence, an N-terminal extension, the VEGF homology domain 
(VHD), and a C-terminal extension that has cysteine-rich sequences resembling insect silk 
proteins (Li and Eriksson 2001). After the signal sequence has been removed, two VEGFC 
precursors are held together by intermolecular disulfide bonds to form an anti parallel 
homodimer. Subsequently, this dimer undergoes a series of proteolytic processes that increase 
the protein binding affinity to VEGFR3 and VEGFR2 (Figure 1.5) (Joukov, Sorsa et al. 
1997). Firstly, VEGFC precursor is divided between Arg227 and Ser228 into nearly equal 
halves, aN-terminal (-31 kDa) and a cysteine-rich C-terminal (-29 kOa) polypeptides, by 
furin convertase (Siegfried, Basak et al. 2003) or plasmin (McColI, Baldwin et al. 2003). 
10 
Chapter 1 Alessandra Agnese Dccio 
Then, a proteolytic cleavage between the growth factor domain and the silk domain activates 
VEGFC binding to VEGFR3 and the N-terminal propeptide is removed extracellularly 
(Joukov, Sorsa et al. 1997). Finally, mature VEGFC is given rise and it is composed of two 
VEGF homology domains bound by non-covalent interactions (Figure 1.5) (Joukov, Sorsa et 
al. 1997). 
1.3.3 Lymphatic versus vascular endothelial response to VEGFC 
VEGFC binds to VEGFR3 and VEGFR2 cell-surface-receptor tyrosine kinases that are 
predominantly expressed on lymphatic and vascular endothelial cells, respectively 
(Kaipainen, Korhonen et al. 1995). Lymphatic endothelium also expresses VEGFR2, which 
might contribute to signalling for mitogenesis (Stacker, Achen et al. 2002). In particular, the 
secreted 31 kD VEGFC protein predominantly activates VEGFR3 whereas the mature, fully 
processed 21 kD form additionally activates VEGFR2 (Joukov, Sorsa et al. 1997). 
Depending on the degree of proteolytic processing of VEGFC precursor, and on the 
expression of its receptors in the lymphatic versus blood endothelial cells of the target tissue, 
the lymphangiogenic versus angiogenic responses to VEGFC are induced. Signalling via 
VEGFR3 alone is sufficient for the lymphangiogenic signals, since VEGFC C156S, which 
only activates VEGFR3 but not VEGFR2, induced a similar phenotype (Veikkola, Jussila et 
al. 2001). VEGFCNEGFR3 interaction (Kaipainen, Korhonen et al. 1995; Joukov, Sorsa et 
al. 1997) induces growth, migration, and survival of primary lymphatic endothelial cells 
(Makinen, Veikkola et al. 2001). 
VEGFC also has synergistic effects with VEGF A during the induction of angiogenesis, and 
this effect is more prominent in cells that express both of its receptors (Pepper, Mandriota et 
al. 1998). 
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Like VEGF A, VEGFC stimulates the migration of endothelial cells and induces vascular 
permeability and endothelial-cell proliferation (Joukov, Pajusola et al. 1996; Joukov, Sorsa et 
al. 1997). 
VEGFR3 deficient embryos succumb due to vascular defects (Dumont, Jussila et al. 1998). In 
addition, VEGFC affects early vascular development in the chorioallantoic membrane before 
the emergence of the Iymphatics. Finally, angiogenesis is enhanced in the ischemic limb and 
in the cornea by VEGFC (Cao, Linden et al. 1998; Witzenbichler, Asahara et al. 1998; 
Marconcini, Marchio et al. 1999). 
The VEGFRs have a similar organization; an extracellular domain composed of 
immunoglobulin (Ig)-like loops for ligand-binding, a transmembrane domain, a cytoplasmic 
juxtamembrane domain, a catalytic tyrosine kinase domain split by a kinase insertion domain 
and a C-terminal tail (Figure lA) (Koch, Tugues et al. 2011). Previous studies have indicated 
that VEGFC binding requires Jg-Loops 1 and 2 in VEGFR3 (Jeltsch, Karpanen et al. 2006), 
whereas binding to VEGFR2 involves Loops 2 and 3 (Leppanen, Prota et al. 20 I 0). Since 
VEGFC can bind to more than one receptor, this allows for the potential formation ofreceptor 
hetero- and homodimers (Dixelius, Makinen et al. 2003; Nilsson, Bahram et al. 2010). 
Indeed, VEGFC can induce the formation and activation of VEGFR3 homodimers and 
VEGFR2NEGFR3 heterodimers, but not VEGFR2 homodimers, that can be induced by 
VEG FA (Nilsson, Bahram et al. 2010). 
1.3.4 Physiological and pathological role of VEGFC 
VEGFC is produced by different tissues during embryogenesis (e.g. lung, heart and skin) and. 
adult life (e.g. macrophages) (Figure 1.6). 
It has a role in the development of the lymphatic vessels in embryos, since deletion of the 
VEGFC gene results in embryonic lethality because of failure of lymphatic vessel 
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development. Furthermore, a paracrine expressIOn pattern is seen between VEGFC and 
VEGFR3 at sites in which the first lymphatic sprouts occur (Kukk, Lymboussaki et al. 1996). 
In the adult, the lymphatic vasculature is rather quiescent, and survival of lymphatic 
endothelial cells is no longer dependent on VEGFR3 signalling (Karpanen, Wirzenius et al. 
2006). Under normal physiological conditions the de novo formation of lymphatic vasculature 
is restricted to the endometrium during pregnancy. 
However, in several pathological situations, including wound healing, tissue repair and organ 
transplant rejection new lymphatic vasculature is generated. 
Lymphatic vessels have a major role in some diseases such as lymphedema and, in particular, 
cancer. 
Lymphedema is the accumulation of fluid in the intersititum of the tissues and can be caused 
by a number of factors relating to lymphatic function (Baldwin, Stacker et al. 2002). In 
particular, in primary lymphedema patients, VEGFR3 has been shown to contain mutations 
which alter the function of the receptor, including autophosphorylation, and prevented signal 
transduction after ligand stimulation, thus stopping the activation of downstream effector 
genes (Ferrell, Levinson et al. 1998; Irrthum, Karkkainen et al. 2000; Karkkainen, Ferrell et 
al. 2000). Furthermore, both Vegfc alle1es are required for normal lymphatic development. In 
Vegfc +/- mice it was observed that VEGFC haploinsufficiency resulted in lymphedema in 
adult mice (Karkkainen, Ferrell et al. 2000). 
1.3.5 VEGFC in cancer 
Regarding the role of VEGFC in cancer, tumor cells disseminate into the Iymphatics via 
invasion into pre-existing lymphatic vessels in the surrounding tissue or by invasion of 
intratumoral lymphatics (Stacker, Achen et al. 2002; Achen, McColl et al. 2005). Both 
peritumoral and intratumorallymphangiogenesis increase the number of the lymphatic vessels 
13 
Chapter 1 Alessandra Agnese Decio 
around the primary tumor and increases contact between the lymphatic endothelial cells and 
tumor cells (Ji 2007). The microenvironment of the tumor, the stroma, and inflammatory cells 
produce multiple lymphangiogenic growth factors that may stimulate tumor-induced 
lymphangiogenesis (Joukov, Pajusola et al. 1996). The expression of VEGFC correlates with 
lymphatic metastasis in multiple human cancers, including prostate, gastric, thyroid, 
colorectal, esophageal, and lung carcinoma (Stacker, Achen et al. 2002; Stacker, Baldwin et 
al. 2002; Achen and Stacker 2008). 
VEGFC overexpression in turnors increases intratumoral Iymphangiogenesis, which has been 
correlated with enhanced metastasis to regional lymph nodes and distant sites (Karpanen, 
Egeblad et af. 2001; Mandriota, Jussila et al. 2001; Skobe, Hawighorst et al. 2001). VEGFC 
has been reported to induce hyperplasia and dilation of tumor lymphatic vessels (Mandriota, 
J ussila et al. 2001; Skobe, Hawighorst et af. 2001), increase in lymphatic density (Dadras, 
Paul et al. 2003), increase in flow rates of lymph (Hoshida, Isaka et al. 2006; Harrell, Iritani 
et af. 2007), and even to induce metastasis to lymph nodes in previously non-metastatic tumor 
cells. Interestingly, lymph node lymphangiogenesis has been observed even before the onset 
of metastasis. Recent studies have demonstrated that lyrnphangiogenesis occurs not only at 
the primary site, but also within draining lymph nodes, prior to tumor cells arriving in the 
lymph node (Qian, Berghuis et af. 2006; Harrell, Iritani et al. 2007; Hirakawa, Brown et al. 
2007; Van den Eynden, Vandenberghe et al. 2007). 
Tumor-released VEGFC may travel via the lymphatics to draining lymph nodes where it 
induces lymphangiogenesis within the lymph node and expansion of the lymphatic network 
(Rinderknecht and Detmar 2008). Thus, lymphangiogenic growth factors derived from the 
primary tumor prepare the lymph nodes for future metastasis (Qian, Berghuis et al. 2006; 
Hirakawa, Brown et al. 2007; Rinderknecht and Detmar 2008); the arrival of turnor cells to 
the lymph nodes further enhances VEGFC-induced lymphangiogenesis. 
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The lymphatic system may also directly facilitate tumor cell recruitment into lymphatic 
vessels. Factors expressed in LECs may facilitate tumor cell invasion, similar to the directed 
migration of Iymphocytes into the lymphatic vessels (Petrova, Makinen et al. 2002; 
Podgrabinska, Braun et al. 2002). 
The expression of VEGFC has been observed in several tumors, such as breast cancer, 
cervical cancer, colorectal cancer, gastric cancer, non-small-cell lung cancer and pancreatic 
cancer (Stacker, Achen et al. 2002), while the expression ofVEGFR2 and VEGFR3 by cancer 
cells is still controversial. Indeed, it has been shown that a wide variety of cancer cells such as 
oral squamoid cancer (Matsuura, Onimaru et af. 2009), gallbladder cancer (Chen, Jiang et al. 
20 I 0), breast cancer (Issa, Le et al. 2009) and gastric cancer (Kodama, Kitadai et al. 2008) 
expressed VEGFR3 and VEGFR2, suggesting that the role of VEGFC signaling pathways 
extends beyond lymphangiogenesis and angiogenesis (Su, Yang et al. 2006). On the other 
hand, it was reported that VEGFR2 and VEGFR3 are localized primarily to intratumoral 
blood and lymphatic vessels but not on malignant cells in human solid tumors (Smith, Baker 
et al. 20 I 0). 
1.3.6 VEGFC in ovarian cancer 
The involvement of VEGFC in ovarian cancer progression is stilI debated. It has been shown 
that tissue expression of VEGFC is associated with peritoneal and lymph node metastases and 
matrix metalloprotease-2 (MMP2) expression in ovarian carcinoma patients (Nishida, Yano et 
al. 2004; Ueda, Hung et al. 2005; Huang and Sui 2012). 
Tissue over-expression of VEGFR3 reflects the aggressiveness of ovarian carcinoma spread 
and has predictive value for identifying high-risk patients with poor prognosis (Klasa-
Mazurkiewicz, Jarzab et al. 2011). Recent studies evidenced dysfunctional lymphatic vessels 
in mesentery and diaphragm of mice transplanted with human ovarian carcinoma cells (Jeon, 
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Jang et al. 2008). However, no significant relation between lymphatic microvessel density and 
overall survival or disease-free survival in patients was evidenced (Schoppmann, Horvat et al. 
2002; Sundar, Zhang et al. 2006). 
Despite all these evidences, the biological significance of VEGFC in ovarian cancer 
progression remains uncertain. 
1.4 Ovarian cancer therapy 
1.4.1 Cytoreductive surgery 
Ovarian cancer is associated with the highest case-fatality ratio of all gynecologic cancers, 
reflecting a propensity for early peritoneal dissemination, and advanced disease at clinical 
diagnosis. Thus, surgery continues to have a major role in the management of patients with 
ovarian cancer, both for accurate staging and for removal of bulk disease (cytoreduction). 
The surgical staging included peritoneal washings and aspiration of ascites for cytologic 
analysis, hysterectomy and bilateral salpingo-oophorectomy, pelvic and para-aortic lymph 
node sampling, diaphragmatic biopsies, omentectomy, biopsy of suspicious lesions and 
random biopsies through the peritoneum. Such a comprehensive laparotomy is essential since 
postoperative treatment is based on clinicopathologic features documented at surgery. In 
addition to accurate staging, the initial surgery is important to remove as much disease as 
possible (cytoreduction). Optimal cytoreduction is considered to have been accomplished 
when no tumor nodule greater than 1 cm remains after surgery (Ozols 2003). 
Numerous studies have demonstrated that the bulk of residual disease after surgery correlates 
with prognosis (Ozols, Rubin et al. 2000). Moreover, the timing of cytoreduction is becoming 
a critical issue. Cytoreduction at the time of diagnosis is a standard practice, although only 
approximately 50% of patients can be effectively cytoreduced at the initial laparotomy. 
Patients in whom the initial cytoreduction was not successful, receive three cycles of 
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chemotherapy, and then if they have a response to treatment, undergo another attempt at 
cytoreduction (interval cytoreduction) followed by additional chemotherapy (van der Burg, 
van Lent et al. 1995). Those patients undergoing interval debulking surgery had a statistically 
significant improvement, both in time to progression and in median survival (6 months). 
An alternative approach to initial cytoreduction consists of neoadjuvant chemotherapy In 
patients with advanced-stage disease. 
Ovarian cancer is frequently considered to be a chronic disease, and while cure remains the 
ultimate goal of cancer therapy, prolongation of survival, together with palliation of 
symptoms, is a clinically meaningful accomplishment. 
1.4.2 Chemotherapy 
The 2010 consensus meeting defined standard of care in ovarian cancer. The recommended 
treatment paradigm for advanced disease has been de bulking surgery followed by platinum-
based chemotherapy, initially cisplatin-based and more recently with carboplatinlpaclitaxel 
(Stuart, Kitchener et al. 2011). 
Platinum-derivatives were introduced as chemotherapeutic agents in 1960s. Cisplatin was the 
first platinum-based drug developed, before carboplatin, a drug with fewer and less severe 
side effects introduced in the 1980s, and oxaliplatin. 
Cisplatin is a cytotoxic drug, classified as alkylating agent whose mechanism of action is the 
formation of a platinum complex interacting with DNA. The formation of DNA adducts, 
primarily intrastrand crosslink adducts, activates several signal transduction pathways and 
culminates in the activation of apoptosis. 
Pac1itaxel was isolated in 1967 from the bark of the Pacific yew tree, Taxus brevi/olia. 
Together with docetaxel, it forms the drug category of the taxanes. Paclitaxel is a mitotic 
inhibitor that stabilizes microtubules (tubulin dimers) and as a result, interferes with the 
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normal breakdown of microtubules during cell division because chromosomes are thus unable 
to achieve a metaphase spindle configuration. This blocks progression of mitosis, and 
prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G-phase 
of the cell cycle without cell division. 
The consensus meeting 20 I 0 acknowledged that acceptable variations to the recommended 
therapies existed, but their use must be supported by at least one trial demonstrating 
superiority or noninferiority. Initially, improvements to standard platinum/taxane 
chemotherapy were seen through the addition of a third chemotherapeutic agent with 
demonstrable activity in the relapsed setting. First-line trials investigated the addition of 
drugs, including pegylated liposomal doxorubicin (PLO), topotecan and gemcitabine 
(Bookman, Brady et al. 2009; Bolis, Scarfone et al. 2010; du Bois, Herrstedt et al. 20 I 0; 
Hoskins, Vergote et al. 2010)), but unfortunately demonstrated only increased toxicity 
without survival benefits. 
Pegylated liposomal doxorubicin IS a new available formulation of doxorubicin, an 
anthracycline antibiotic intercalating DNA, that is encapsulated in a pegylated liposome. The 
size of the Iiposomes prevents them from entering tissues with tight capillary j unctions, such 
as the heart and gastrointestinal tract and in contrast to other nanoparticles, the pegylation 
allows these molecules to be protected from destruction by reticuloendothelial system. 
Topotecan is a derivative of camptothecin that inhibits topoisomerase I, thus blocking cell 
cycle S-phase. 
Gemcitabine is a nucleoside analog of deoxycytidine that replaces cytidine, during DNA 
replication, thus blocking DNA synthesis and inducing apoptosis. 
Recently, trabectedin demonstrated efficacy as second-line treatment in platirmm-sensitive 
ovarian cancer. The mechanism of action is binding the DNA minor groove and interfering 
with cell division, gene transcription mechanisms and DNA repair (Colombo 2011). 
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A more successful strategy seems likely to be the addition of targeted therapies to 
chemotherapy. 
1.4.3 Targeted therapies 
During the least years the search for new cancer therapies has been addressed to the 
development of specific target drugs that block cancer growth and dissemination by 
interfering with multiple molecular targets such as growth factor receptors, signal 
transduction pathways, cell cycle regulators, and angiogenic mechanisms specifically 
expressed by tumor cells or tumor environment. For this reason, these therapies are very 
effective on cancer cells and less harmful to normal cells. 
Two of the major molecular targeted agents applied to ovarian cancer treatments are inhibitors 
of angiogenesis (chapter 1.5) and the PARP inhibitor Olaparib, a potent oral inhibitor of 
poly(adenosine diphosphate [ADP]-ribose) polymerase that induces synthetic lethality In 
BRCA 1I2-deficient tumor cells (Evers, Drost et al. 2008; Rottenberg, Jaspers et al. 2008). 
1.5 Inhibitors of angiogenesis 
Angiogenesis is a complex process similar to the above described lymphangiogenesis. 
Angiogenesis is the formation of new blood vessels from existing ones: as described for 
lymphatic endothelial cells, vascular endothelial cells proliferate, migrate and penetrate host 
stroma, generating capillary sprouts. 
In the adult, physiological angiogenesis is involved in normal processes. Examples of 
physiological angiogenesis are in the formation of the uterus lining prior to menstruation in 
females and of the placenta after fertilization, and wound healing (Carmeliet and Jain 2000). 
Angiogenesis is a critical component for the growth and metastasis of cancer (Ellis and 
Hicklin 2008) and it is one of the hallmarks of cancers that have been extensively studied 
(Hanahan and Weinberg 2011). 
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Angiogenic factors control a discrete step called the "angiogenic switch", required for the 
induction of tumor vasculature (Hanahan and Folkman 1996). It has been widely recognized 
and shown that the angiogenic switch occurs when a tumor reaches approximately 1-2 mm2, a 
critical size for the progression of its growth (Folkman 1995). Angiogenesis is tightly 
controlled by an angiogenic balance between molecules that promote angiogenesis (e.g., 
VEGFA, fibroblast growth factor) and those that inhibit angiogenesis (e.g., thrombospondin-
1) (Figure 1.7) (Hanahan and Folkman 1996). 
During pathological angiogenesis the tight balance and control of factors which regulated the 
process are lost and turnor vessels fail to remain quiescent (Bergers and Benjamin 2003). 
Adequate tumor blood supply plays an important role in controlling the invasion of the 
metastatic cells in secondary sites. Indeed, experimental evidence showed that tumor 
vascularization correlates with high malignancy and bad prognosis, and that elevated levels of 
angiogenic factors, for example vascular endothelial growth factor (VEGF) and basic-
fibroblast growth factor (bFGF/FGF-2), are associated with tumor growth (Giavazzi, Sennino 
et al. 2003; Dowlati, Gray et al. 2008; Ghosh, Sullivan et al. 2008). 
Angiogenesis is important also for supporting tumor growth, as blood supply provides the 
tumor's main access to nutrients and oxygen at both primary and secondary sites. 
VEGF A expression is higher in ovarian cancer tumors than in normal ovarian tissue or benign 
ovarian pathologies (Manenti, Riccardi et al. 2005). 
Angiogenesis is more studied than lymphangiogenesis, thus a greater number of inhibitors is 
now available. Nevertheless, some inhibitors are able to target both pathways, for example, 
agents targeting members ofthe VEGF family. 
In order to inhibit the VEGF pathway, there are two primary strategies: (1) inhibition of the 
VEGF ligand with antibodies or soluble receptors and (2) inhibition of the VEGF receptors 
(VEGFR) with tyrosine kinase inhibitors (TKls), or receptor antibodies (Figure 1.8). 
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The most investigated VEGF inhibitor is a humanized monoclonal antibody that binds the 
VEGF ligand, knOMl as bevacizumab (Avastin). It has recently been approved in Europe as a 
first-line treatment of advanced ovarian cancer in combination with chemotherapy, as several 
phase III studies showed that bevacizumab is active in ovarian cancer (Aghajanian, Finkler et 
al. 2011; Burger, Brady et al. 2011; Perren, Swart et al. 2011; Pujade-Lauraine, Hilpert et al. 
2012). 
1.5.11nhibitors of lymph angiogenesis 
Several preclinical studies have investigated whether specific inhibition of the 
VEGFC/VEGFR3 pathway might inhibit cancer metastasis to lymph nodes and beyond. 
Inhibition of VEGFR3 activity by anti-VEGFR3 antibodies reduced the incidence of lymph 
node and organ metastasis in a mouse breast carcinoma model (Roberts, Kloos et al. 2006). 
As VEGFR3 may also have a role in turnor angiogenesis, the use of a VEGFR3-specific 
antibody has been shoMl to reduce primary tumor growth (Laakkonen, Waltari et al. 2007). 
Furthermore, inhibition of tumor cell VEGFC expression by stably transfected small 
interfering RNA reduced lymphangiogenesis, lymph node, and lung metastasis of murine 
mammary cancers (Chen, Varney et al. 2005). As an alternative approach, soluble VEGFR3 
fusion protein (VEGFCID-trap) has been shoMl to inhibit VEGFC-induced tumor 
lymphangiogenesis and metastatic spread in a breast cancer xenotransplant model (Karpanen, 
Egeblad et al. 2001). Overexpression of soluble VEGFR3 by lung cancer cells also reduced 
the number of intratumoral lymphatic vessels and the incidence of metastasis to the draining 
lymph nodes (He, Kozaki et al. 2002). Ectopic overexpression of soluble VEGFR3 in an 
immunocompetent rat mammary tumor model suppressed metastasis formation in lymph 
nodes and lungs (Krishnan, Kirkin et al. 2003). More recently, a gene therapy approach using 
recombinant adeno-associated virus expressing soluble VEGFR3 resulted in blockade of 
21 
Chapter I Alessandra Agnese Decio 
lymph node metastasis in a melanoma model in mice (Lin, Lalani et al. 2005). Furthermore, a 
small molecule with high selectivity for VEGFR3, SAR131675, has been described to reduce 
Iymphangiogenesis, angiogenesis, and tumor-associated macrophages (T AM) infiltration and 
consequently reduce tumor growth and metastasis in preclinical models (Alam, Blanc et al. 
2012). 
The double inhibition of VEGFR2 and VEGFR3 by combining the anti-VEGFR2 and anti-
VEGFR3 antibodies more potently decreased lymph node and lung metastases than each 
antibody alone in a mouse breast carcinoma model (Roberts, Kloos et al. 2006), suggesting 
that a combination therapy with antiangiogenic agents may be a particularly promising 
approach for controlling metastases (Roberts, Kloos et al. 2006). 
In particular, preclinical data in ovarian cancer suggested that inhibition of VEG FR 1, 
VEGFR2 and VEGFR3 by gene therapy significantly reduced tumor size (Sallinen, Anttila et 
al. 2009; Sallinen, Anttila et al. 2011; Sopo, Anttila et al. 2012). 
A number of small molecule kinase inhibitors of VEGFR2 have been found to also inhibit 
VEGFR3 signal transduction, including sunitinib, cediranib, sorafenib, PTKlZK, MAZ51 and 
CEP-7055. These small molecular compounds also affect, however, a number of other 
tyrosine kinases, and their distinct effects on tumor lymphangiogenesis in vivo remain to be 
investigated. 
There are several anti-angiogenic/anti-lymphangiogenic drugs under investigation in ovarian 
cancer. For example, tyrosine kinase inhibitors targeting VEGFRs and PDGFR (BIBFlI20, 
cediranib, dorafenib, vandetanib and jl-lOl), an anti-angiopoetin antibody (AMG386) and 
VEGF-trap (Collinson, Seligmann et al. 2012) . 
1.5.2 Cediranib 
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Among VEG F receptors tyrosine kinase inhibitors, cediranib is one of the most promising 
compound. 
Cediranib (AZD2171) is an oral, small molecule tyrosine kinase inhibitor that inhibits all the 
three VEGF receptors (VEGFRl, VEGFR2 and VEGFR3), PDGFR-a!PDGFR-~, FGFR-I 
and c-kit. 
Cediranib was described effective in reducing lymphatic metastasis, independently of the 
effect on blood vessels (Padera, Kuo et al. 2008), but also blocking VEGFC-induced 
VEGFR3 activity and lymphangiogenesis in lung cancer (Heckman, Hyngstrom et al. 2008). 
Cediranib competes for the A TP-binding site within the receptor kinase domain (Heckman, 
Holopainen et al. 2008), inhibiting VEGFC-induced phosphorylation of VEGFR3 and 
VEGFR2 in primary human endothelial cells. Consequently, a reduced activation of 
downstream signaling molecules ERK1I2, Akt, and CREB is observed. Additionally, cellular 
functions associated with VEGFR activation, including proliferation, survival, and migration, 
are all compromised by cediranib. Interestingly, cellular migration seems to be particularly 
sensitive to cediranib treatment. Low concentrations of the compound inhibit lymphatic and 
blood endothelial cell migration, but only slight inhibition of ligand-induced receptor 
phosphorylation at the same concentration was observed. Furthermore, cediranib 
compromises the growth of both tumor associated lymphatic and blood vessels. Growth of 
human non-small cell lung adenocarcinoma tumors in cediranib-treated animals is impaired 
(Heckman, Holopainen et al. 2008). 
Cediranib has shown activity on human tumor xenografts. Encouraging preclinical data 
supported clinical testing in patients with a broad range of advanced cancers. 
In the randomized, double-blind NCIC clinical trial BR24 study on advanced non-small-cell 
lung cancer (NSCLC), the addition of cediranib to carboplatinlpaclitaxel resulted in improved 
response and PFS (Goss, Amold et al. 2010). 
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In the double-blind, randomized phase III study (HORIZON Ill) on advanced metastatic 
colorectal cancer, cediranib activity, in terms of progression-free survival (PFS) and overall 
survival (OS), was comparable to that ofbevacizumab when added to mFOLFOX6. However, 
the predefined boundary for PFS noninferiority was not met (Schmoll, Cunningham et al. 
2012). 
Cediranib monotherapy was studied in a phase 11 study in patients with recurrent 
glioblastoma. Encouraging proportions of radiographic response, 6-month progression-free 
survival were observed after cediranib treatments (Batchelor, Mulholland et al. 2010). 
Cediranib monotherapy demonstrated significant evidence of antitumour activity In a 
randomised phase II study in patients with advanced renal cell carcinoma (Mulders, Hawkins 
et al. 2012). 
In a prospective trial of systemic therapy for metastatic alveolar soft part sarcoma, it was 
observed that cediranib has substantial single-agent activity, producing an objective response 
rate (ORR) of 35% and a disease control rate of 84% at 24 weeks (Kummar, AlIen et al. 
2013). 
In an open-label, phase I study of cediranib in patients with acute myeloid leukemia, cediranib 
showed preliminary evidence of activity as a monotherapy (Fiedler, Mesters et al. 2010). 
In particular, in ovarian cancer cediranib has demonstrated widespread activity as 
monotherapy in two phase IJ single- agents studies with either platinum-resistant or -sensitive 
recurrent EOC (Hirte, Vidal et at. 2008; Matulonis, Berlin et al. 2009). A multi-stage phase 
III Gynaecologic Cancer InterGroup (GCIG) trial, ICON6, has now completed the 
recruitment of women with platinum-sensitive relapsed ovarian cancer. ICON6 is evaluating 
the safety and efficacy of platinum-based chemotherapy alone versus chemotherapy with 
concurrent and maintenance cediranib for 18 months. The primary outcome measure for stage 
I was safety: it has demonstrated that is feasible to add cediranib to carboplatinlcisplatin 
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(DDP) and paclitaxel chemotherapy without major unexpected toxicities (Raja, Griffin et al. 
2011). Trial completion is expexted in October 2013. 
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Aim of the study 
Epithelial ovarian cancer is still a leading cause of cancer death because of difficulties in 
diagnosis and lack of effective therapies. 
Thus there is an ongoing need to identify selective pathways and investigate targets for 
therapy. 
The aim of the study is to investigate the role of VEGFC and VEGFR3 in ovarian cancer 
invasion and metastasis. It proposes to address such an idea by employing a panel of patient-
derived human ovarian carcinoma xenografts spontaneously releasing VEGFC in biological 
fluids, that reproduces the features of ovarian cancer patients. Furthermore, the effects on 
tumor growth and metastasis induced by VEGFC are studied on human ovarian carcinoma 
cell lines infected to over-express VEGFC, directly comparing the wild-type and the VEGFC 
over-expressing tumors. 
Altogether, the aims of this project are to: 
• characterize models of human ovarian tumor xenografts growing in the peritoneal cavity 
and under the bursa of the ovary of immunodeficient mice focusing on their pattern of 
invasion and metastasis; 
• investigate the role of the VEGFC and VEGFR3 axis in ovarian cancer cell growth and 
invasive phenotype; 
• inhibit the VEGFCNEGFR3 pathway. 
26 
VEGF-D VEGF-A j EGF\/ PDGF-BB 
FGF-2 
I / HGF I 0 
• • VEGFR-3 Nrp2 VEGFR-2 Tie2 Tie1 FGFR-3 HGF-R PDGFRoIp 
LYMPHANGIOGENESIS 
IGF-2 
IGF-1 
/ AM / 
IGF-1R 
RAMP2 UlNL Calerl 
Figure 1.1 Representation of Iymphangiogenic growth factors and their 
receptors expressed by lymphatic endothelium. Several vascular endothelial 
growth factors (VEGFA, VEGFC, VEGFD) promote lymph angiogenesis by 
activation of VEGF receptors-2 and -3 (VEGFR2, VEGFR3) and neuropilin-2 
(Nrp2). Additional lymphatic growth factors include angiopoietin-l (ANG-l), 
hepatocyte growth factor (HGF), fibroblast growth factor-2 (FGF-2), insulin-like 
growth factors (IGF-l , IGF-2), platelet-derived growth factor-BB (PDGF-BB), 
and adrenomedullin (AM). From lurisic and Detmar 2009. 
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Figure 1.2 Vascular endothelial growth factor (VEGF) family and their 
receptors. VEGF family members bind to specific receptor tyrosine kinases 
VEGFRl , VEGFR2, and VEGFR3 and, through activating different cascades, 
exert their various biologic effects, From Masoumi Moghaddam, Amini et al. 
2012. 
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Figure 1.3 Exon-intron organization of human VEGFC gene and other 
members of the VEGF family. CA) The exons a re shown as boxes and their 
lengths in bp are indicated. White boxes, noncoding porti ons; hatehed boxes, 
signa l sequences; grey boxes: sequences encoding C- and N-terminal pro peptidcs 
that a re removed during successive steps of proteo lyti c processing; black boxes, 
sequences encoding the full y processed YEGFC po lypeptide. The cysteine moti fs 
encoded by the different exons are indicated above the boxes. The translati onal 
start (ATG) and stop (TAA) codons are marked in bold face type, as is the 
polyadenylation signal (pA) . The TAA stop codon in the 5th exon refers to the 
a lternati ve ly spliced mRNA form lacking exon 4 , which is a lso marked. The 
putati ve mRNA form lacking exons 2-4 is indicated with the broken line. (B) The 
structures o f the YEGF, YEGFB, and PIGF genes are shown fo r compari son. 
Black boxes indicate the cooling region, and the striped box indicates the ex on 
encoding part of the heparin-bind ing region. The bars are drawn to sca le. 
Modifi ed fro m Chilov, Kukk et al. 1997. 
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Figure 1.4 The protein structure of growth factors and receptors associated 
with Iymphangiogenesis. Two members of the vascular endothelial growth 
factor (VEGF) family (VEGFC and VEGFD) are implicated in 
lymph angiogenesis - VEGF is shown for comparison. These are secreted 
homodimeric polypeptides that contain a hydrophobic amino-terminal signal 
sequence for protein secretion (Sig). All VEGF family members contain a central 
region that is termed the VEGF homology domain (VHD) and contains a 
cysteine-rich motif. A subfamily of these growth factors contains VEGFC and 
VEGFD, defined by their ability to bind VEGFR3 and the presence of amino-
and carboxy-terminal propeptides (N-Pro and C-Pro). The receptors for VEGFC 
and VEGFD are VEGFR2 and VEGFR3, both of which can be expressed on 
lymphatic endothelial cells. These receptors are closely related in structure, 
consisting of an extracellular domain with seven immunoglobulin-like domains 
(Ig), a transmembrane domain (TM), a split tyrosine kinase domain (TK) with a 
kinase insert sequence (KI) and a cytoplasmic tail (CT) at the carboxyl terminus. 
The fifth Ig-like domain ofVEGFR3 is proteolytically processed and the subunits 
are held together by a disulphide bond (-S-S-). From Stacker, Achen et a1. 2002. 
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Figure 1.5 Schematic model of the proteolytic processing of VEGFC. 
Schematic model of the proteolytic process ing of vascular endothelial growth 
factor C (VEGFC). The regions of the nascent VEGF-C precursor pol ypeptide are 
the signal sequence (SS, black box), N-terminal propeptide (N-TP), VEGF-
homology domain (VEGF-H, gray box) and C-tenninal propeptide (C-TP). 
Putative sites of N-linked glycosylation (Y) are shown; black ovals mark the Cys 
residues conserved among the platelet-derived growth factor (POGF)/VEGF 
famil y of growth factors; the repeated cysteine residue motifs in the C-terminal 
pro peptide are not marked for clarity. Numbers indicate molecular masses (kO) of 
the corresponding polypeptides in reducing conditions. Oisulfide bonds joining 
the N- and C-terminal propeptides are marked as -S-S-; noncovalent bonds as 
dofled lanes. It is currently not known how the N-terminal cleavages are 
regulated and how much of the VEGF-C present in tissues is partially versus 
completely processed. Some intermed iate forms are also omitted to simplify the 
scheme. From Enholm, Juss ila et al. J 998. 
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Figure 1.6 Mode of action of Jymphangiogenic growth factors. The 
Iymphangiogenic growth factor vascular endothelial growth factor C (VEGFC) is 
produced by a range of cells and tissues during embryogenesis, adult life and 
certain pathologies, including cancer. The full-length growth factor is processed 
by as yet uncharacterized proteases that cleave the amino- and carboxy-terminal 
propeptides (light blue and red L-shapes, respectively) from the VEGF homology 
domain (VHD) to generate a mature form that consists of dimers of the VHD 
(purple oval) that bind the receptors VEGFR2 and VEGFR3 with high affinity. 
Activation of VEGFR3 induces lymphangiogenesis, whereas activation of 
VEGFR2 is thought to drive angiogenesis. From Stacker, Achen et al. 2002. 
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Figure 1.7 Angiogenesis is a balance between pro- and anti-angiogenic factors. 
In most tissues, angiogenesis is held in check by tightly regulated amounts of pro-
(activators) and anti- (inhibitors) angiogenic factors. From Zetter 2008. 
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Figure 1.8 VEGF signaling inhibitors and their targets. The VEGF family of 
ligands (VEGFA, PlGF, VEGFB, VEGFC, and VEGFD) bind to their cognate 
receptors (VEGFRl; blue, VEGFR2; grey, VEGFR3; green) as indicated 
(arrows). Several different VEGF antagonists interfere with binding of VEGF 
ligands on the extracellular domain (e.g. Bevacizumab, VEGF-Trap, Veglin, 
IMC-18Fl, Ramuciumab/CDP791), or compete for ATP-binding to the 
intracellular kinase domain (e.g. axitinib, brivanib, cediranib, linifanib, 
pazopanib, sorafenib, sunitinib, tivozanib, vandetanib, vatalanib). VEGFRs are 
shown with their extracellular domain organized in immunoglobulin-like loops 
(circles, labeled 1- 7) and with intracellular split tyrosine kinase domain 
(squares). From Tugues, Koch et al. 2011. 
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2.1 Drugs and Reagents 
Cediranib (AZD2171, AstraZeneca, Alderley Park, Macclesfield, UK) was dissolved in 
OM SO (lOOOX stock solution) for in vitro studies and further diluted in test medium 
immediately before in vitro assays (control cells received the same amount of DMSO). For in 
vivo treatments, cediranib was suspended in 1 % Tween-80 (Sigma-Aldrich, Milan, Italy) by 
gentle shaking with 6-mm glass beads at room temperature overnight, and the suspension 
used within one week of preparation. 
Paclitaxel (PTX, Indena S.p.A., Milan, Italy) was dissolved in 50% polyxyethylated castor oil. 
(Cremophor EL, Sigma-Aldrich, Milan, Italy) and 50% ethanol and further diluted with 0.9% 
saline before use. 
Cisplatin (cis-diamminedichloroplatinum, DD?, Sigma-Aldrich, Milan, Italy) was dissolved 
in 0.9% saline before use. 
Recombinant VEGFR3IFc chimera (R&D Systems, Minneapolis, MN) was reconstituted in 
PBS 0.1 % BSA (20X stock solution). 
2.2 In vitro studies 
2.2.1 eel/lines and culture conditions 
The human ovarian carcinoma cell line lA9, a variant derived from the A2780 human ovarian 
carcinoma cell line (Manenti, Riccardi et al. 2005) and IGROVl (Benard, Da Silva et al. 
1985) were obtained from National Cancer Institute, Fredrick, MD. 
Stocks of cell lines, authenticated by short-tandem repeat profiling (AmpFlSTR Identifiler 
Plus PCR Amplification Kit; Applied Biosystems, Monza, Italy), were stored frozen in liquid 
nitrogen. 
Cells were resurrected from the cell bank by rapid thawing (to 37°C in a water bath), the vial 
containing the cells in cryogenic medium (Lonza, Walkersville, MD) and the contents were 
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counted by Trypan blue exclusion (Fluka Analytical, Sigma-Aldrich, Milan, Italy) and 
transferred to a fresh tube. About 10 ml of fresh medium containing 10% of heat-inactivated 
fetal bovine serum (FBS, Bio Whittaker, Lonza, Walkersville, MD) was added. After 
centrifugation, cells were transferred to a T25 tissue culture flask in 5-ml fresh culture 
medium containing RPMI 1640 (BioWest-Voden Medical, Milan, Italy) supplemented with 
10% FBS (Bio Whittaker, Lonza, Walkersville, MD) and 2 mM L-Glutamine (L-Glutamine 
lOOX solution, 200 mM, BioWest-Voden Medical, Milan, Italy). Once resurrected from the 
cell bank, cells were allowed to go through at least 2-4 passages before being used. Cells were 
maintained in a CO2 incubator at 37°C with 5% CO2 and were passaged routinely twice a 
week, to maintain logarithmic growth. 
Cell culture procedures were carried out aseptically in a class 11 laminar flow cabinet and the 
cells were tested for Mycoplasma contamination upon thawing. 
Lentivirus-infected cells were cultured as the wild-type cells with the addition of selection 
antibiotic in culture medium to select infected cells. 
Selection antibiotics were: 
Blasticidin for luciferase-infected cells, 5 Jlg/ml (Invitrogen, Life-Technologies, 
Monza, Italy); 
Neomycin for VEGFC-infected cells, 500 Jlg/ml (BioWhittaker, Lonza, WalkersviIle, 
MD); 
Zeocin for Katushka-infected cells, 1 Jlg/ml (lnvitrogen, Life-Technologies, Monza, 
Italy). 
The mouse lymphatic endothelial cell line (MELC), expressing VEGFR3 was provided by 
Annunciata Vecchi (Istituto Clinico Humanitas, Rozzano, Italy) and maintained as previously 
described (Sironi, Conti et al. 2006), in DMEM (Bio West-Voden Medical, Milan, Italy) 
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supplemented with 1 mM L-Glutamine (BioWest-Voden Medical, Milan, Italy), 1% MEM 
Non-Essential Amino Acids (NEAA, Sigma-Aldrich, Milan, Italy), 1 mM Sodium Pyruvate 
(Sigma-Aldrich, Milan, Italy), penicillin-streptomycin (Bio Whittaker, Lonza, Walkersville, 
MD), 10% FBS (Bio Whittaker, Lonza, Walkersville, MD), 100 Ilglml ECGS (Harbor Bio-
Products, Norwood, MA), 100 Ilglml heparin (Hospira Italia S.r.l., Napoli, Italy), and 10% 
supernatant from sarcoma 180 cells. All the plastics used for lymphatic endothelial cell 
culture were pre-coated with 1 % gelatin in PBS (37°C for at least 2 h). 
The 293FT is a cell line used for lentivirus production. The stable expression of the SV40 
large T antigen (Naldini, Blomer et al. 1996) makes the 293FT cell line a particularly suitable 
host for generating lentiviral constructs. The 293FT cell line was kindly provided by Enrico 
Pesenti (Nerviano Medical Sciences Oncology, Nerviano, Italy) and maintained in high-
glucose DMEM (BioWest-Voden Medical, Milan, Italy), supplemented with 10% FBS 
(Bio Whittaker, Lonza, Walkersville, MD), 0.1 mM MEM Non-Essential Amino Acids 
(NEAA, Sigma-Aldrich, Milan, Italy), 6 mM L-Glutamine (BioWest-Voden Medical, Milan, 
Italy) and 1 mM MEM Sodium Pyruvate (Sigma-Aldrich, Milan, Italy). 
2.2.2 Generation oflentivirus-infected cells 
The generation of lentivirus-infected cells was performed in collaboration with Nerviano 
Medical Sciences Oncology, Nerviano, Italy. 
2.2.2.1 Plasmids 
The lentiviral vector carrying the coding sequence of synthetic firefly luciferase gene luc2 
(Photinus pyralis, kindly provided by Enrico Pesenti, Nerviano Medical Sciences Oncology, 
Nerviano, Italy) was integrated into a pLenti6.3N5-DEST destination vector, expressing the 
Blasticidin resistence gene (Invitrogen, Life-Technologies, Monza, Italy). The expression 
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clone pLenti-Luc was obtained by Gateway® Technology (Invitrogen, Life-Technologies, 
Monza, Italy, Figure 2.1). The Gateway® Technology is a universal cloning method based on 
the site-specific recombination properties of bacteriophage lambda and is a rapid and highly 
efficient way to move DNA sequences into multiple vector systems for functional analysis 
and protein expression (Landy 1989). 
Using the same technology, the lentiviral vector carrying the coding sequence of Katushka, a 
far-red mutant of the red fluorescent protein from sea anemone Entacmaea quadricolor 
(Shcherbo, Merzlyak et al. 2007) (Evrogen, Moscow, Russia) was integrated into a 
pLenti6.3N5-DEST destination vector, modified to express the Zeocin resistence gene 
(Invitrogen, Life-Technologies, Monza, Italy) and the expression clone pLenti-Kat was 
obtained. 
Finally, the coding sequence of the full-length VEGFC isoform (VEGFCfl, 1290 bp) or its 
proteolitically activated mature form (VEGFCmf, 490 bp) (Joukov, Sorsa et al. 1997; Skobe, 
Hamberg et al. 2001), kindly provided by Michael Detmar (ETH - Institut f. Pharmazeut. 
Wissenschaften, ZUrich, Switzerland), were integrated into pLenti6.3N5-DEST expression 
vectors, modified to express the Neomycin resistance gene, using Gateway® technology. The 
expression clones pLenti-VEGFCfl or pLenti-VEGFCmfwere obtained. 
2.2.2.2 Lentivirus stock production 
Replication-incompetent, HIV -I-based lentivirus were created to deliver and express the 
genes of interest (luciferase, Katushka and VEGFCfl or VEGFCmt) in ovarian cancer IA9 or 
IGROVl cells. 
The optimized 293FT producer cell line, that stably expresses the SV40 large T antigen under 
the control ofthe human CMV promoter, facilitates optimal production of virus. 
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239FT cells were plated in a 10 cm tissue culture plate in order to have a 90-95% cell 
confluence on the day of transfection. The day of transfection culture medium was removed 
from the 293FT cells and replaced with Opti-MEM medium (Invitrogen, Life-Technologies, 
Monza, Italy). 
A transfection cocktail containing 9 J-lg of the Packaging Mix (3 J-lg pLP 1, 3 J-lg pLP2 and 3 J-lg 
pLPNSVG) and 3 J-lg ofpLenti expression plasmid DNA was diluted in 1.5 ml of Opt i-ME M 
medium. 
pLPl contains gag and pol genes: gag is the viral core proteins required for fonning the 
structure of the lentivirus (Luciw 1996), pol is the viral replication enzyme required for 
replication and integration of the lentivirus (Luciw 1996). Expression of the gag and pol 
genes from pLP 1 has been rendered Rev-dependent by virtue of the HIV -1 RRE in the 
gag/po I mRNA transcript. pLP2 contains the HIV-l Rev ORF that encodes the Rev protein 
that interacts with the RRE on pLPl to induce Gag and Pol expression, and on the pLenti6/V5 
expression vector to promote the nuclear export of the unspliced viral RNA for packaging into 
viral particles. pLPNSVG contains the gene that encodes the envelope G glycoprotein from 
Vesicular Stomatitis Virus to allow production of a pseudotyped retrovirus with a broad host 
range (Emi, Friedmann et af. 1991; Bums, Friedmann et af. 1993; Yee, Miyanohara et al. 
1994). 
36 J-l1 of Lipofectamine™ 2000 were diluted in 1.5 ml of Opti-MEM medium and after 5 
minutes of incubation at room temperature, the diluted Lipofectamine™ 2000 was combined 
with the diluted DNA. 
After 20 minutes of incubation at room temperature the DNA-Lipofectamine™ 2000 
complexes were added to 293FT cells. Cells were incubated overnight at 37°C in a humidified 
5% C02 incubator. Recommended guidelines for working with BL-2 organisms as infectious 
virus were used. 
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Medium containing the DNA-Lipofectamine™ 2000 complexes was removed after 24 hours, 
replaced with 1 0 ml complete culture medium and incubated at 37°C in a humidified 5% CO2 
incubator. Virus-containing supernatants were harvest 48-72 hours post-transfection, 
centrifuged at 3000 rpm for 15 minutes at 4°C and stored at -80°C. 
2.2.2.3 Cells transduction 
lA9 and IGROVl cells were plated in complete media as described in section 2.2.1. 
Lentiviral stock was thawed, and after removing the culture medium from the cells, the virus 
was added. Hexadimethrine bromide (Sigma-Aldrich, Milan, Italy) was added to a final 
concentration up to 10 Ilg/ml, as it enhances transduction. After swirling the plate to mix, it 
was incubated overnight at 37°C. After 24 hours, the medium containing virus was removed 
and replaced with complete culture medium. After 24 hours, complete medium containing the 
appropriate amount of Blasticidin, Zeocin or Neomycin was added to select for stably 
transduced cells selection. Antibiotic-resistant cells were selected after 10-12 days. 
The absence of viral particles was verified by ELISA (Alliance HIV-l P24 Antigen ELISA 
Kit, Perkin Elmer, Waltham, MA). 
2.2.3 In vitro bioluminescence imaging 
To verify whether bioluminescent signal intensity correlated with the cell number, cells were 
seeded at increasing concentration, ranging from Ix106 to 3.125x104, in a 96-well black plate. 
D-Luciferin substrate (I50 Ilg/ml, Caliper Lifescience, Alameda, CA) was added into the cell 
medium and bioluminescence signal detected 10 min later by eXplore Optix MX2 (ART, 
Advanced Research Technologies Inc., Saint-Laurent, Canada). Photon emission was 
recorded as pseudo-color images representing the spatial distribution of detected photon 
counts emerging from active luciferase within the well and quantified using Optiview 
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software (version 2.02.00; ART, Advanced Research Technologies Inc., Saint-Laurent, 
Canada). The mean value of BLl signal detected in each well was plotted against the number 
of cells seeded in the well. 
2.2.4 Supernatant collection 
Cells were plated in 6-wells culture plates at the concentration of 5 x 104 cells (lA9 cell line 
variants) or 1 x 105 cells (IGROVl cell line variants) per well in RPMI 1640 supplemented 
with 10% FBS. After 48h hours at 37°C, mono layers were washed twice with Ca- and Mg-
free PBS (BioWest-Voden Medical, Milan, Italy) and 1 ml of RPM I without FBS was added. 
Conditioned media were collected after 4, 24 and 48 hours, centrifuged at 1200 rpm for 10 
minutes at 4°C, aliquoted and stored at -80°C until use. 
2.2.5 Growth curve 
Cells were plated in 96-wells culture plates (1-2 x 103 cells/well) in RPMI 1640 supplemented 
with 10% FBS. After 4, 24, 48, 72 or 96 hours cells were fixed and stained with 0.5% crystal 
violet in 20% methanol. The stain was eluted with a solution 1: 1 of 0.1 M sodium 
citrate/ethanol and the absorbance was read at 595 nm. Absorbance was proportional to the 
number of ceIls. 
Doubling time (DT) was calculated according to the A TCC animal cell culture guide, as OT = 
T x 1n2 / In (Xe-Xb) where T is the incubation time, Xb is the cell number (Abs) at the 
beginning of incubation time and Xe is the cell number (Abs) at the end of incubation time. 
2.2.6 lvfolilily assay 
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Motility of mouse lymphatic endothelial cells or ovarian carcinoma cells in response to 
conditioned medium was assayed using modified Boyden chambers and 8 ~m pore size 
polycarbonate polyvinylpyrrolidone-free nucleopore filters (Taraboletti, Belotti et al. 1993). 
Conditioned medium of VEGFC infected cells obtained from an equal cell number was used 
as attractant. 
5 x 105 cellslml in Dulbecco's modified Eagle's medium (DMEM, BioWest-Voden Medical, 
Milan, Italy) 10.1 % BSA were added to the upper compartment of the chamber. Cediranib (la 
nM, section 2.1) or recombinant VEGFR3/Fc chimera (10 ~glml, section 2.1) were added to 
the cells and incubated overnight throughout the assay. 
Filters were stained with Diff-Quick (Merz-Dade, DUdingen, Switzerland), and the cells 
migrated in 10 high-power fields were counted. Data are expressed as number of migrated 
cells (mean ± SD of triplicates). 
2.2.7 l.Iultiplex in situ Epitope Profiling (MiSEP) 
The expression levels of VEGFRl, VEGFR2 and VEGFR3 on cell surfaces were measured 
by MiSEP technology (LEAP Biosciences, Mountain View, CA, Figure 2.2) that 
simultaneously detected multiple receptors on living cell surfaces. The receptor expression 
levels were determined by quantifying antibodies that were bound to their receptors. 
Antibodies specific to the extracellular domain (ECD) of VEGFR1, VEGFR2 and VEGFR3 
were incubated with cells. Receptor-bound antibodies were then eluted from their receptors to 
derive the receptor-profiled antibody sample' and then quantified by ECD array using 
Luminex xMAP® system. The amount of each antibody in the sample reflected the 
abundance of each receptor on the cell surface. Assays were conducted according to 
manufacturer's instructions. All samples were analyzed in duplicate. 
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2.2.8 ELISA assay 
The levels of human VEGFC in cell supernatants and in serum and ascites of nude mice 
bearing human ovarian tumors were determined by ELISA (Quantikine®, R&D Systems, 
Minneapolis, MN), according to manufacturer's instructions. The sensitivity of the assay was 
13,3 pg/ml. Each sample was analyzed in duplicate. The results were expressed in pg/ml. 
2.2.9 Real-Time peR 
VEGFC, VEGFR3 and VEGFR2 transcripts were analyzed by real-time reverse transcription-
PCR (RT-PCR) using TaqMantF'J Gene Expression Assay (Applied Biosystems, Monza, Italy). 
Briefly, total RNA was extracted from turnor cells and tumor masses snap frozen in liquid 
nitrogen with Trizol® protocol (Invitrogen, Life-Technologies, Monza, Italy), then purified 
and reverse-transcribed with Archieve kit (Applied Biosystems, Monza, Italy) to cDNA, 
according to manufacturer's instructions. Experiments were run in triplicate. Amplification 
reactions were performed with the 7900HT Fast Real Time PCR System (Applied 
Biosystems, Monza, Italy). PCR data were analyzed using the Sequence Detection Systems 
(SDS) version 2.3 (Applied Biosystems, Monza, Italy). VEGFC, VEGFR3 and VEGFR2 
mRNA were normalized to HPRTI or beta-actin housekeeping gene: ~Ct = Cttarget-
Cthousekeeping. Data are expressed as T ~Ct x 1000 or T ~Ct x 100 (Schmittgen and Livak 2008), 
mean ± SO ofthree replicates from one experiment representative of three. 
2.3 In vivo studies 
2.3.1 Human ovarian cancer xenografts 
Patient-derived human ovarian cancer (HOC) xenografts (high-grade serous HOC8, HOC22, 
HOClO and the endometroid-clear cell HOC79) were established and maintained by 
intraperitoneal transplantation in nude mice (Massazza, Tomasoni et al. 1989). These 
44 
Chapter 2 Alessandra Agnese Decio 
xenograft models were molecularly, biologically and pharmacologically characterized 
(Nicoletti, Lucchini et al. 1993; Valoti, Nicoletti et al. 1998) and stored as frozen stocks at 
early passages after establishment. 
2.3.2 Animals 
Six- to eight-week-old female NCr-nulnu mice were obtained from Harlan (Correzzana, 
Italy). Mice were maintained under specific pathogen-free conditions, housed in isolated 
vented cages, and handled using aseptic procedures. Procedures involving animals and their 
care were conducted in conformity with institutional guidelines that comply with national 
(Legislative Decree 116 of January 27, 1992, Authorization n.19/2008-A issued March 6, 
2008, by the Italian Ministry of Health) and international laws and policies (EEC Council 
Directive 86/609, OJ L 358, 1, December 12, 1987; standards for the Care and Use of 
Laboratory Animals, United States National Research Council, Statement of Compliance 
A5023-0 1, October 28, 2008) and in line with Guidelines for the welfare and use of animals 
in cancer research (Workman, Aboagye et al. 2010). 
2.3.3 Intraperitoneal tumor models 
Patient-derived ovarian cancer cells (described in section 2.3.1) were obtained by harvesting 
and centrifuging at 1200 rpm for 10 minutes at 4°C the ascites of at least three-five mice. 
Pellets of cells were pooled, resuspended in HBSS (Bio West-Voden Medical, Milan, Italy) 
and again centrifuged. Then cells were counted by trypan blue exclusion with the aid of a 
BUrker chamber and resuspended in HBSS at the concentration of 5 x 107 cells/m!. 
A suspension of 0.2 ml (l0 x 106 cells) was injected intraperitoneally in the lower right 
quadrant of abdomen using a syringe with a 21 gauge needle. The day of inoculation was 
considered to be day O. 
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Mice were checked twice a week for tumor formation (abdominal distension) in the peritoneal 
cavity, and killed when moribund (Garofalo, Naumova et al. 2003). 
2.3.4 Intraovarian tumor models 
lA9 and IGROVl variants were grown to semi-confluence in tissue culture as described in 
section 2.2.1. Once harvested with trypsinelEDT A (trypsin 0.05% w/v EDTA 0.02% w/v, 
BioWest-Voden Medical, Milan, Italy), cells were pooled and quantified. Detached cells were 
re suspended in RPMI 1640 with 10% FBS and washed three times with HBSS (BioWest-
Voden Medical, Milan, Italy). Then, the cells were counted by trypan blue exclusion with the 
aid of a B ilrker chamber and resuspended in HB SS at the concentration of 2 x 108 cells/ml. 
Nude mice were anesthetized with isoflurane (Florane, Abbott Laboratories, Chicago, IL) and 
a single lateral midline incision allowed access to the left ovary. Ovarian cancer cells were 
implanted orthotopically under the bursa of the ovary of nude mice as a 1 x 106 cell 
suspension in 5 JlI HBSS using a Hamilton syringe with a 26 gauge needle (Fu and Hoffman 
1993; Connolly 2009). The day of inoculation was considered to be day O. 
Mice were checked twice a week for tumor formation in the ovary, and killed when moribund. 
2.3.5 Surgical removal o/primary tumor 
Mice were anesthetized in lateral side with isoflurane. A 2-3 cm lateral midline skin incision 
was made and the ovary and the oviduct were exteriorized. A hemostat was clamped around 
the uterine vasculature between the oviduct and uterus. Each ovary and part of the oviduct 
was removed with single cuts through the oviducts near the ovary. After removing the 
hemostat, the remaining tissue was replaced into the peritoneal cavity. The incision was 
sutured with wound clips. 
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2.3.6 In vivo bioluminescence andfluorescence imaging 
Bioluminescence imaging (BLI) was used to confirm the presence of luciferase-infected 
tumors in the ovary of nude mice and to monitor tumor progression. Nude mice were 
anesthetized with isoflurane and scanned ten minutes after the injection of D-luciferin 
solution (150 mg/kg, i.p.; Caliper Lifescience, Alameda, CA) by eXplore Optix MX2 (ART, 
Advanced Research Technologies Inc., Saint-Laurent, Canada). 
Fluorescence imaging (FLI) was used to confirm the presence of Katushka-infected cells in 
the ovary of nude mice and to monitor tumor progression. Mice were scanned for 
fluorescence using the 635 nm excitation wavelength pulse laser by eXplore Optix MX2 
(ART, Advanced Research Technologies Inc., Saint-Laurent, Canada). 
A region of interest (ROJ) was designed over the peritoneal cavity of each animal, and light 
emission in the selected ROJ was quantified as total photon counts using Optiview software 
(version 2.02.00; ART, Advanced Research Technologies Inc., Saint-Laurent, Canada). 
Photon emission was recorded as pseudo-color images representing the spatial distribution of 
detected photon counts emerging from active luciferase of fluorescent cells within the animal. 
Overlay of the grey-scale (body of reference photograph) and pseudo-color images allowed 
localization of tumors within the animal. For each group and for each time point, the mean 
value of BLI or FLI signal detected in the selected ROI was calculated and plotted against 
days after tumor transplantation in a histogram graph. Tumor burden was expressed as photon 
counts (Oliva, Decio et al. 2012). 
2.3.7 Blood sample collection 
Blood samples were collected at different time points from the superficial temporal vein of 
mice (Figure 2.3). This technique allows to collect blood sample at different time points 
during tumor progression from the same animal. 
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Nude mice were restrained so that the hairless freckle was located on the side of the jaw. 
Then, the freckle was pricked with a 18 gauge needle and quickly blood drops were collected 
in a sterile plastic tube. Blood was incubated 30 minutes at 37°C to activate platelets, 
centrifuged at 3000 rpm for 15 minutes to obtain serum and stored at -80°C until processing. 
2.3.8 In vivo treatments and preclinical trials 
2.3.8.1 Cediranib as monotherapy in IGROVl and HOC xenografts 
IGROVl-luc and IGROVl-lucNEGFCmf tumor-bearing mice were randomized by 
bioluminescence imaging seven days after tumor transplant (8-10 mice in each group). 
Patient-derived HOC8, HOCI0, HOC22 and HOC79 xenografts were randomized 
respectively 7, 10, 6, 5 days after tumor transplant, on the basis of representative mice with 
confirmed tumor burden in the peritoneal cavity by histological analysis. Cediranib was given 
orally at the dose of 6 mg/kg (for IGROVl-luc and IGROVl-lucNEGFCmt) or 3 mg/kg (for 
HOCs), daily for 21 days (Q 1x21), or until survival (day 108, maintenance regimen, detailed 
schedule of treatment in chapter 5, Figure 5.8A). Vehicle was administered following the 
same schedule as the active compound. 
2.3.8.2 Cediranib in combination therapies 
HOe8-bearing mice were randomized seven days after tumor transplant, on the basis of 
representative mice with confirmed tumor burden in the peritoneal cavity by histological 
analysis. Mice were treated with standard chemotherapy, PTX and DDP (PTX+DDP, at the 
dose of 10 mg/kg and 3 mg/kg, respectively), for three cycles (Q7x3) and cediranib (3 mg/kg, 
daily) was administered according to different schedules: 
a) in combination with chemotherapy, started on day 7 (Qlx21), Figure 5.9A; 
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b) in combination with chemotherapy, started on day 7, and continued until day 90 (Qlx83), 
Figure 5.9A; 
c) alone, or in combination with chemotherapy, started on day 22 (24h after the end of the 
chemotherapy) and continued until day 90 (Qlx68), Figure 5.l0A. 
Detailed schedules, doses and lengths of treatment are reported in chapter 5 (Figures 5.9A and 
5.l0A). Vehicles were administered at the same schedule as the active compounds. 
2.3.9 Treatment evaluation 
For IGROV1-luc and IGROV1-lucNEGFCmf-bearing mice, tumor burden and progression 
were monitored by bioluminescence imaging (BLI), as described in section 2.3.6. 
Patient-derived xenografts (HOC8, HOC I 0, HOC22 and HOC79) bearing mice were 
monitored and checked twice a week for tumor formation (abdominal distention) in the 
peritoneal cavity. 
For ethical reasons, survival was defined as the day of appearance of signs of distress, at 
which time mice were euthanized (Garofalo, Naumova et al. 2003; Oliva, Decio et al. 2012). 
At necroscopy, the peritoneal cavity was macroscopically examined to ascertain the presence 
of tumor. Survival time was recorded and increment of life span (lLS) was calculated as 100 
x [(median survival day of treated group - median survival day of control group) / median 
survival day of control group]. Results were plotted as the percentage survival against days 
after tumor transplant. Complete response, confirmed macroscopically at necropsy, was the 
absence of tumour in animals still alive 60 days after the death of the last mouse in the same 
group. 
2.3. J 0 Necroscopy 
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Mice were sacrificed and necropsied to establish tumor burden. Macroscopical analysis of the 
organs of the peritoneal cavity was performed and gross findings were recorded. 
Venous blood was collected and serum for soluble VEGFC and VEGFRs analysis was 
obtained as described in section 2.3.7. 
Ascites was harvested, centrifuged at 1200 rpm for 10 minutes and the volume of fluid and 
number of cells in the pellet (representative oftumor burden) recorded for each mouse. Serum 
and ascites were stored at -80 DC until processing (Manenti, Riccardi et al. 2005). 
For histopathological and immunohistochemical analysis, organs (para-aortic lymph nodes, 
ovaries and diaphragms) were formalin-fixed and paraffin-embedded (section 2.4.1). 
Pellet of cells after ascites centrifugation and tumor tissues were immediately frozen in liquid 
nitrogen for mRNA extraction and gene expression analysis (section 2.2.9). 
2.4 Ex-vivo analysis 
2.4.1 Histological and immunohistochemical analysis 
Histological and immunohistochemical analysis were done in collaboration with Veronica 
Patton and Rachele Alzani from Nerviano Medical Sciences Oncology, Nerviano, Italy. 
Para-aortic lymph nodes, ovaries and diaphragms were collected, fixed in 10% phosphate-
buffered formalin (Bio Optica Milano S.p.A., Milan, Italy) and embedded in paraffin with the 
aid of a microwave rapid tissue processor (Histos5, Milestone S.r.l., Sorisole, Italy). Organs 
were cut into 5 Ilm-thick sections and stained with hematoxylin and eosin (H&E). 
For immunohistochemistry an anti-human VEGF Receptor 3 rabbit polyclonal antibody 
(Abeam, Cambridge, UK), an anti-mouse L YVE-I rabbit polyclonal antibody (Abeam, 
Cambridge, UK) and anti-mouse CD31 rat monoclonal antibody (Dianova GmbH, Ilamburg, 
Germany) were used. L YVE-l positive vessels were not labeled with anti-CD31 antibody, 
confirming their lymphatic identity. For LYVE-l, a morphological analysis of stained 
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lymphatic vessels was done, considering positive vessels in lymph nodes, ovaries/tumors and 
diaphragms, and their location and dilation. The presence of neoplastic emboli within 
lymphatic vessels was recorded. For CD3l five fields/turnor were counted at 400x 
magnification. Fields were selected in highly vascularized turn or areas. Every lumen lined by 
positive endothelial cells and/or endothelial clusters clearly stained and separated from 
adjacent clusters was counted as a single microvessel. 
2.4.2 Mouse soluble VEGF receptors assay 
Murine soluble VEGFRl, VEGFR2 and VEGFR3 were measured in serum of nude mice 
bearing human ovarian carcinoma tumors by luminex kit (Milliplex® MAP kit, Millipore 
S.p.A., Vimodrone, Italy), according to manufacturer's instructions. The sensitivity of the 
assay was 76.2 pg/ml for soluble VEGFRl, 32.6 pg/rnl for soluble VEGFR2 and 41.5 pg/ml 
for soluble VEGFR3. Each sample was analyzed in duplicate. The results were expressed as 
relative release: [amount VEGFR (pg/mt) at day x] / [amount VEGFR (pg/ml) at 
randomization]. 
2.5 Statistical analyses 
Statistical analyses were done using Prism Software (prism 5.01; GraphPad Software, La 
Jolla, CA). Differences in VEGFC levels, in VEGFRs levels, in photon counts and cell 
migration were analysed by two-way ANOVA followed by Bonferroni post-test. Differences 
in growth curves were analyzed by Multiple t tests. Correlations between a) VEGFC levels 
and tumor burden and b) VEGFRs levels and tumor burden and c) photon intensity and the 
number of cells in vitro were assessed using the Pearson's correlation coefficient. Differences 
in mouse survival time were analyzed by the Log-Rank test. 
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Figure 2.1 Gateway technology. This technology uses the lambda 
recombination system to facilitate transfer of heterologous DNA sequences 
(flanked by modified att sites) between vectors (Hartley, Temple et al. 2000). 
Two recombination reaction constitute the basis of the Gateway® Technology. 
(A) BP reaction : facilitates recombination of an auB substrate (aIlB-PCR product 
or a linearized allB expression clone) with an attP substrate (donor vector) to 
create an aUL-containing entry clone. This reaction is catalyzed by BP Clonase™ 
enzyme mix. (B) LR Reaction: Facilitates recombination of an attL substrate 
(entry clone) with an attR substrate (destination vector) to create an attB-
containing expression clone. This reaction is catalyzed by LR Clonase™ enzyme 
mix. 
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3.1 Introduction and goals 
Preclinical animal models of cancer are one of the most important tools to study tumors. In 
particular, mice are used because they are comparative living systems that allow researchers 
to discover the underlying basis of how and why cancers arise, why primary tumors 
metastasize, and how various kinds of preventive interventions and treatments can be used to 
stop the progression of cancer, or the growth and spread of tumors, and prolong patient lives. 
Four main categories of cancer models are generally used in preclinical investigations, namely 
genetically engineered models (GEMs), syngeneic murine models (both induced or 
spontaneously arisen), xenograft:s obtained from human tumor specimens from patients 
(patient-derived tumor xenografts, PDTX), directly transplanted into immunodeficient mice, 
without an intermediate in-vitro passage, and xenografts derived from well-established and 
characterized human tumor cell lines cultured in vitro. 
Each of these models has advantages and disadvantages. 
GEMs often concern specific molecular targets highly suited to preclinical assessment of the 
corresponding targeted compounds, as tumor growth occurs spontaneously in situ and in 
organspecific sites. This reproduces the situation observed in human cancers and interactions 
between tumor and stroma, as well as the impact of the immune system, appear to closely 
mimic human situations. However, assessment of therapeutic efficacy could be hampered in 
the case of non superficial or delayed tumor growth and by the fact that the GEMs represent 
only one model of the tumor-specific target, which does not necessarily predict that the target 
itself will be coupled to the biological 'read-out' in real human cancers (Peterson and 
Houghton 2004). 
Syngeneic murine models provided the first opportunity for large scale screemng for 
antitumor drugs. These models allow to consider the involvement of immune system in cancer 
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development and progression. A drawback is that these syngeneic models grow so rapidly that 
their applications are limited (Langdon 2012). 
PDTX maintain the molecular and genetic heterogeneity typical of the human tumor of origin 
(TentIer, Tan et al. 2012); the majority of the key genes and global pathway activity in 
primary tumors is maintained (lones, Zhang et al. 2008; Daniel, Marchionni et al. 2009). 
Furthermore, the original tumor architecture and histological characteristics are preserved 
(Massazza, Tomasoni et al. 1989; Daniel, Marchionni et al. 2009). 
POTX have also a good correlation with clinical outcome (Fiebig, Maier et al. 2004; Gorelik, 
Ziv et al. 2008), as procedures for assessment of therapeutic efficacy have been well 
standardized and readily allow evaluation of combined therapies, particularly for the purposes 
of objective biostatistical assessment (Decaudin 2011). Indeed when combined with 
mathematical modelling, these results can be applied to individualise treatment for the 
patients from which these tumours are obtained (Gorelik, Ziv et al. 2008). 
A drawback of POTX models is that although the original tumor architecture is maintained 
the human stroma is replaced by murine stroma with sequential passage (Tentler, Tan et al. 
2012). 
Human tumor cell lines, obtained establishing and culturing in vitro cells from tumor tissues 
from patients, once transplanted in mice in the orthotopic site grow as the original tumor 
maintaining the same behavior (Moro, Bertolini et al. 2012). 
Cell lines are widely used to explore new aspects of cancer biology, from the role of 
individual molecules, to the role of cellular processes involved in invasion and metastasis 
within animal models. They are easy to use, grow rapidly, produce reproducible results and 
have a strong track record of use in cancer research. For experimental use or compound 
screening for a target mechanism it is certainly possible to change the phenotype of cell lines 
by ex-vivo manipulations before xenotranplantation to create variants that reflect better the 
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biology of their parent lines (Cree, Glaysher et al. 2010; Decaudin 2011). Unfortunately, there 
is increasing recognition that their relevance to human cancer may not be all it seems, and 
results from cell lines of a particular lineage rarely correlate with the sensitivity of that tumor 
type to the drugs tested. 
Cell lines are adapted to grow in cell culture medium, which provides a very different 
environment to that which they experienced in their originating tumor (Fernando, Glaysher et 
al. 2006), resulting in genetic changes that are distinct from the genetic stress imposed on 
tumors in patients (Daniel, Marchionni et al. 2009). The expression of these changed genes is 
not restored when derivative cell line is returned to grow in vivo (Daniel, Marchionni et al. 
2009). Likewise, there is strong evidence that a greater genetic divergence exists between a 
primary tumor and the corresponding cell line derived from that tumor, versus a direct 
xenograft after several generations (Daniel, Marchionni et al. 2009). 
Within tumors, cancer cells are normally capable of independent growth and show reduced 
attachment to substrate (usually basement membrane proteins) and to other cells. In contrast, 
cell lines may become dependent on growth factors supplied as serum or other supplements 
and adherence to plastic. Withdrawal of serum or use of plastics such as polypropylene, which 
do not encourage cell adherence results in the death of many cell lines (Cree, Glaysher et al. 
2010). 
The highly anaplastic cancer cells cultivated in vitro represent the extreme derivates from 
highly advanced cancers and are not associated with original tumor stroma, which now has 
been recognized as a crucial factor in the pathogenesis of cancer metastasis (Bhowmick, 
Neilson et al. 2004). 
GEM, syngeneic models, PDTX and tumor cell line models are complementary, as each of 
them gives particular information on the different aspects of cancer growth and dissemination. 
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In this chapter two different and complementary models used to investigate different features 
of turn or growth and metastasis induced by the VEGFCNEGFR3 pathway are described: 
1. Patient-derived ovarian carcinoma xenografts established in this laboratory and 
implanted in the peritoneal cavity of nude mice. 
2. Human ovarian carcinoma cell lines implanted orthotopically under the bursa of the 
ovary of immunodeficient mice. 
Part of the work presented is a manuscript in press in American Journal of Pathology, 
2014. 
3.2 Patient-derived ovarian carcinoma xenografts 
HOC xenografts are high grade serous (HOC8, HOC22, HOCI0) and endometroid-clear cell 
(HOC79) ovarian cancer (Massazza, Tomasoni et al. 1989) derived from untreated (HOC8 
and HOCIO) and treated (HOC22 and HOC79) patient and established intraperitoneally (i.p.) 
in nude mice (Table 3.1). When transplanted into the peritoneal cavity of nude mice they 
produce ascites and carcinomatosis, recapitulating the behavior of the original patients' 
tumors. These xenografts were molecularly and pharmacologically characterized for the 
response to chemotherapy in this lab. 
3.2.1 Correlation between tumor burden and VEGFC 
The expression of VEGFC was analyzed in the four ovarian tumor xenografts. Tumor 
xenografts were transplanted i.p. in nude mice. Mice were killed with a heavy tumor burden, 
biological fluids harvested, and the amount of VEGFC measured by ELISA assay. All the 
four tumor xenografts released soluble VEGFC both in ascites and serum at sacrifice (Figure 
3.1). Comparable VEGFC levels were detected in ascites ofHOC8, HOCI0 and HOC22 (256, 
214 and 223 pg/ml, respectively) while VEGFC detected in ascites of HOC79 was lower (69 
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pg/ml). VEGFC was detectable also in serum of HOC8, HOC 10 and HOC22 (66, 68 and 87 
pg/ml, respectively). Since the ELISA assay recognized specifically human (not mouse) 
VEGFC, this VEGFC was certainly produced by the tumor cells. 
The relationship between soluble VEGFC levels and tumor progression was investigated in 
HOC8 xenograft. Nude mice (n=7 for each time point) were transplanted i.p. with HOC8 
cells. Ascites was harvested 13, 21, 35, 43 and 55 days after tumor transplantation and the 
amount of VEGFC was measured by ELISA assay. The levels of VEGFC in ascites rose with 
time after tumor injection, showing a strong correlation with tumor burden, expressed as 
number of cells in the peritoneal cavity (Figure 3.2A, R2=0.9082, ***p<0.0005). Serum 
VEGFC peaked 21 days after transplant (173 pg/ml, Figure 3.2B). 
3.2.2 Para-aortic lymph nodes invasion 
Tumor infiltration of para-aortic lymph node and ovaries was analyzed 21 and 35 days after 
tumor transplant by histological analysis. On day 21, HOC8 cells were found outside the 
lymph nodes (Figure 3.3A) and by 35 days 69% of the lymph nodes (n=14) were massively 
invaded by neoplastic cells (Figure 3.3B and Table 3.2). The capsule of invaded lymph nodes 
was intact, suggesting that tumor cells reached the nodes through lymphatic and/or blood 
vessels rather than directly from the peritoneal cavity. This path of dissemination was also 
supported by the detection of turnor cells inside diaphragmatic lymphatic vessels (L YVE-1+) 
and peritoneal blood vessels (CD31+) (Figure 3.3C and 3.30). 
A tendency of lymph nodes to present with enlarged lymphatic vessels before the arrival of 
metastatic cancer cells was evidenced by L YVE-l immunostaining 21 days after tumor 
transplantation (Figure 3.4). 
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3.3 Set up of orthotopic intraovarian models 
In order to set up an orthotopic model of human ovarian cancer growing in the ovary of 
immunodeficient mice, lA9, a variant derived from A2780 (Manenti, Riccardi et al. 2005) 
and IGROVl (Benard, Da Silva et at. 1985) human ovarian carcinoma cells were injected 
under the bursa of the ovary. The accuracy of transplant was confirmed by the presence of 
some ovarian structures (follicles with oocytes) in neoplastic masses (Figure 3.5). lA9 and 
IGROV1-transplanted mice were sacrificed and necropsied at day 20 and at day 28, 
respectively. 
Histopathological analysis of ovaries and lymph nodes indicated that the tumor take of lA9 
cells was 3 out of 4 (75%). No metastases were observed in the contralateral ovaries or into 
the para-aortic lymph nodes (Table 3.3). A tumor take of 4 out of 4 (100%) was observed for 
IGROVl cells, 66% of mice with metastasis into the contralateral ovary, while the presence 
of metastatic cells was not revealed in para-aortic lymph nodes (Table 3.3). 
The expression of human VEGFC and its receptor human VEGFR3 in lA9 and IGROVl cell 
lines was analyzed by Real-Time PCR. VEGFC transcript was not detectable in lA9 nor in 
IGROVl, while VEGFR3 was expressed in both the cell lines (Figure 3.6). 
3.3.1 Surgical removal of primary tumor 
The standard first-line therapy for ovarian cancer patients is cytoreductive surgery followed 
by chemotherapy (Cannistra, Bast et at. 2003). In order to reproduce a more accurate model 
of ovarian cancer, surgical removal of primary tumor in the ovary was performed and tumor 
dissemination and mice survival evaluated. 
Specifically, lA9 tumor cells were injected under the bursa of the ovary. Fourteen days after 
tumor cell injection, primary tumor was surgically removed from half ofthe mice. 
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Increased survival was observed in mice undergoing surgery, with an ILS of 37% (Median 
survival time - MST control 41 days, MST Surgery 56 days, Figure 3.7). 
However, histopathological analysis of ovaries and lymph nodes indicated that the 100% of 
tumors relapsed. As observed in control mice, no metastases were observed in the 
contralateral ovaries or into the para-aortic lymph nodes (Table 3.4). 
Removal of the primary tumor resulted in increased mice survival, although the tumor regrew 
rapidly and no differences in the metastatic pattern were observed. 
3.4 Summary of results 
The data presented in this chapter can be summarized as follows: 
HOCs 
• Patient-derived xenografts transplanted in nude mice release soluble VEGFC which 
circulates at high levels in the serum and ascites of mice bearing the xenografted 
tumors. 
• In the HOC8 model the amount of VEGFC released in ascites correlates with tumor 
burden 
• Peak of VEGFC is observed in serum 21 and 35 days after transplant and correlates 
with lymph nodes invasion. 
• Lymphatic vessels from tumor bearing mice are enlarged in lymph nodes before the 
arrival of metastatic cancer cells. 
Intraovarian models 
• lOO% tumor take is observed after 1 A9 and I GRO V 1 cells transplantation. 
• lA9 and IGROVl cells do not express human VEGFC, but do express human 
VEGFR3. 
• No metastasis in lymph nodes are observed. 
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• Surgical removal of intraovarian primary tumor increases mice survival but does not 
influence tumor growth and metastasis. 
3.5 Discussion 
Mouse models recapitulate many aspects of the genesis and progression of human cancers, 
thus they are valuable resources to investigate the mechanisms of cancer and to predict 
clinical behavior. 
In this chapter, models of human ovarian carcinoma xenografts were set up and characterized. 
To study a correlation between tumor progression and VEGFC expression, VEGFC was 
measured in patient-derived HOC xenografts, that produce ascites and carcinomatosis to the 
organs of the peritoneal cavity. 
Circulating VEGFC has been recently shown to correlate with ovarian carcinoma progression 
(Cheng, Liang et al. 2013). In the current study, it was shown that VEGFC is released in 
serum and ascites of all four human ovarian carcinoma bearing mice. Furthermore, in the 
HOC8 xenograft VEGFC levels correlated with tumor burden and lymph node invasion, 
suggesting that VEGFC released in biological fluids might serve as an indicator of tumor 
burden and invasion. Particularly interesting was the fact that capsules in invaded lymph 
nodes were intact; the location of turn or cells in the subcapsular sinus just beneath the capsule 
suggests that they reached the lymph nodes from afferent lymphatic vessels and/or blood 
vessels, not directly from the peritoneal cavity. This was supported by immunohistochemical 
findings of tumor cells in lymphatic and blood vessels of the diaphragm and peritoneum. In 
addition, consistent with recent reports (Qian, Berghuis et al. 2006; Alitalo and Detmar 2012; 
Liersch, Hirakawa et al. 2012) observing that VEGFC secreted by primary skin tumors 
induced Iymphangiogenesis and enlargement of lympatic vessels within the draining lymph 
nodes before tumor metastasis (Qian, Berghuis et al. 2006; Hirakawa, Brown et al. 2007), 
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there was a tendency to pre-metastatic lymphatic vessel dilation in para-aortic lymph nodes. 
These results indicate lymphatic vasculature reorganization in sentinel lymph nodes before 
tumor cells arrival and provide clues to the active role of lymphatics in ovarian cancer 
dissemination. 
The limit of patient-derived tumors is that they only grow in vivo by serial propagation in 
mice not allowing genetic manipulation. 
On the contrary, tumor cells lines have the advantage to grow in vitro, they are easily 
infectable with specific genes in order to investigate their functions, or with reporter genes, to 
visualize cells with imaging instruments. 
Given that neither IA9 nor IGROVI cells expressed VEGFC, it was decided to stably infect 
these cells with VEGFC to study its role in ovarian cancer progression, comparing the 
behavior of the infected cell lines with the wild type cells. The characterization of VEGFC 
overexpressing cell lines is described in the next chapter. 
Intraovarian transplant was set up by injecting the cells directly under the bursa of the ovary 
of immunodeficient mice. The orthotopic model reproduces the appropriate tumor 
microenvironment, and mimic tumor-stroma interaction typical of the target organ, allowing 
the emergence of the biological features of ovarian cancer progression, angiogenic process, 
metastatic phenotype, resistance and therapeutic response to therapies similar to those 
observed in patients. A very important limit is the testing of mouse stroma and more 
important, the use of immunocompromised mice that does not allow to consider the 
involvement of immune system in cancer development and progression. 
Usually, ovarian cancer patients undergo surgery to remove primary turnor and later are 
treated with chemotherapy. We therefore reproduced cytoreductive surgery of primary tumor 
in 1 A 9 model, to verify if surgery modified tumor behavior and metastasis, and to explore if 
the model was more representative of the clinical situation. Our results indicated a survival 
64 
Chapter 3 Alessandra Agnese Decio 
advantage of cytoreduced mice, without any differences in the metastatic pattern compared to 
not surgical mice. For this reason, in the following experiments, it was decided not to remove 
the primary tumors from mice. 
In summary, the models described in this chapter are complementary tools that have been 
used to analyze the role ofVEGFC and VEGFR3 in turnor progression and metastasis and to 
study the efficacy ofVEGFCNEGFR3 inhibitors (Chapters 4 and 5 of this thesis). 
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Figure 3.1 VEGFC levels in patient-derived EOC-xenografts transplanted in 
nude mice. Nude mice were transplanted intraperitoneally with the indicated 
H xenografts. VEGFC levels in ascitic fluids (green columns) and serum (red 
column) were assayed by ELISA. Results are the mean ± SD of three mice per 
group. n.a. = not available. 
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Figure 3.2 orrelation between VEGFC levels and tumor progression in 
HO 8 xeno rraft. (A) Nude mice were transplanted intraperitoneally with 
H 8. Tumor burden (number of cells harvested from the peritoneal cavity, 
blue) and V . (green) were measured in ascitic fluids by ELISA. Results are 
the mean ± 0 of three mice per group for each time point. (B) Serum VEGFC 
wa measured at the indicated time after turnor transplant. Results are the mean ± 
o of even mice per group for each time point. 
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Figure 3.3. Tumor cells invasion and localization. (A-B) Representative 
histological images of lymph nodes. Histological analysis at different times after 
tumor transplant showed tumor cells (red arrows) outside (A) and inside (B) para-
aort ic lymph nodes on days +2 1 and +35 respectively. Turnor cells (red arrows) in 
diaphragmatic LYVE- l positive lymphatic vessel (C) and a peritoneal blood 
vessel (D) 21 days after tumor transplant. (A,B,D) Scale bars represent 100 j.lm; 
( ) cale bar represents 50 j.lm. 
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Figure 3.4. Enlarged lymphatic vessels are present before the arrival of 
metastatic cancer cells. An increased number of lymph nodes presenting 
enlarged lymphatic vessels was observed at days 13 and 21 after transplant. 
White and black columns indicated enlarged and not enlarged lymphatic vessels, 
respectively. n= 4-6 mice for each time point. 
69 
Figure 3.5. Accuracy of injection. Representative histological image of some 
ovarian structures (follicles with oocytes, white arrows) recognizable in some 
neoplastic masse thus indicating the accuracy of injection. Scale bar respresents 
50 ~m. 
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Figure 3.6. Expression of hVEGFC and hVEGFR3 in lA9 and IGROVl cell 
lines. RT-PCR. hYEGFC and hYEGFR3 mRNAs were normalized to I-IPRT I 
housekeeping gene: t,Ct = Ct target - Ct 11 PIU! • Data are expressed as 2-~Ct x 1000 
(mean and SO from one experiment representative of three). Experiments were 
run in triplicate. I A9 = white columns; IGROY I = grey columns. n.d. = not 
detectable. 
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Figure 3.7. Survival curve. Effect of primary tumor surgically removal on the 
lifespan of mice bearing IA9 intraovarian tumor. Control mice = black curve; 
surgical mice = red curve. n=6-10, **p<O.OOl. 
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Xenograft Histological Grade Stage Treated 
type 
HOC8 serous G3 IV NO 
HOC 10 serous G3 mc NO 
HOC22 serous G3 mc YES 
HOC79 Endometroid + G3 mc YES 
clear cell 
Table 3.1. Panel of patient-derived EOC-xenografts transplanted in nude 
mice. Clinicopathological characteristics of the tumors from ovarian cancer 
patients. 
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Lymph nodes 
Days after N° LNI re intra2 re extra3 neg4 
transplant mIce (%) (%) (%) 
+ 21 7 14 0(0%) 10 (71 %) 4 (29%) 
+ 35 7 13 9 (69%) 3 (23%) 1 (8%) 
Tablc 3.2. Para-aortic lymph nodes invasion of HOe8 transplanted mice. (1) 
Number of lymph nodes (LN) analyzed. Lymph nodes with tumor cells (re) 
located inside (2, intranodal) or outside (3, extranodal). (4) Lymph nodes negative 
for the presence of tumor cells. 
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Presence ortumor cells IA9 IGROYI 
Tumor take (left ovary) 3/4 (75%) 3/3 (100%) 
Contralateral ovary 0% 2/3 (66%) 
Para-aortic lymph nodes 0% 0% 
Table 3.3. Metastatic behaviour of lA9 and IGROYl cells transplanted 
orthotopically under the bursa of the ovary of nude mice. Histopathological 
analysis of transplanted left ovaries, contralateral right ovaries and para-aortic 
lymph nodes was done at day 20 for lA9 and at day 28 for IGRDVl. Data are the 
number (and percentage) of mice with metastatis over total mice. 
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Presence of tumor cells Contl'ol Surgery 
Tumor take (left ovary) 9/9 (100%) 6/6 (100%) 
Relapse - 6/6 (100%) 
Contralateral ovary 0% 0% 
Para-aortic lymph nodes 119 (11 %) 0% 
Table 3.4. Metastatic behaviour of lA9 intraovarian bearing mice undergoing 
surgery for the removal of primary tumor. Histopathological analysis of 
transplanted left ovaries, relapsed tumor, contralateral right ovaries and para-aortic 
lymph nodes was done at sacrifice. Data are the number (and percentage) of mice 
with metastatis over total mice. 
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4.1 Introduction and goals 
The studies presented in this chapter are aimed to study how VEGFC affects ovanan 
carcinoma progression. 
In the previous chapter, it was shown that neither lA9 nor IGROVl cells expressed VEGFC. 
This fact makes both cell lines good candidates to be manipulated to over-express VEGFC by 
infection and thus studying and clarifying its role in ovarian cancer. 
This chapter is also aimed to establish cell lines over-expressing reporter genes. As one of the 
limits of orthotopic transplant is the difficulty to follow tumor growth and progression, 
especially when tumors are small, infecting cells with reporter genes allows to facilitate the 
visualization of cancer cells in vivo by non-invasive optical imaging. 
Two widely used non-invasive optical imaging techniques are bioluminescence Imagmg 
(BLI) or fluorescence imaging (FLI). 
BLI utilizes native light emISSIOn from one of several organisms which naturally 
bioluminesce, for example the firefly. The DNA encoding the luminescent protein (the 
luciferase enzyme) is incorporated in the target (e.g. tumor cells) and then the substrate (D-
luciferin) is required to be injected to the luciferase carrying target. The chemical reaction that 
occurs is this: D-Iuciferin + ATP + O2 I LUciferase:> Oxyluciferin + Light (photons). 
As the reaction involves ATP, only viable cells can produce light after administration of the 
substrate. 
FLI is based on the integration of an engineered fluorescent protein, essentially a 
fluorochrome, into a target recipient (e.g. tumor cells). This protein fluoresces, emitting 
photons of light after being excited from its ground state to a higher quantum state by a source 
of energy, for example a laser. 
Thus, these two imaging techniques enable visualization of physiological and 
pathophysiological processes at the cellular and molecular level in different mouse models 
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with high specificity. Furthermore, in oncology preclinical research, optical imaging allows to 
visualize tumors, in vivo, and to follow tumor growth and progression in the same mice at 
different time points, avoiding killing animals, thus reducing the number of mice used in the 
experimentation. 
The aims of this chapter are: 
• To establish cell lines over-expressing reporter genes +1- VEGFC. 
• To test VEGFC paracrine and autocrine activities, in vitro, on lymphatic and infected 
ovarian tumor cells respectively. 
• To characterize the VEGFC over-expressing cell behavior in vivo, analyzing tumor 
growth and metastasis. 
Part of the work presented is a manuscript in press in American Journal of Pathology, 
2014. 
4.2 Generation of cell lines over-expressing reporter genes 
Both, lA9 and IGROVI cells were infected with lentiviral vector carrymg the coding 
sequence for luciferase or for Katushka, a far-red mutant of the red fluorescent protein from 
sea anemone Entacmaea quadricolor (Shcherbo, Merzlyak et af. 2007) and bioluminescence 
and fluorescence compared in order to select the best model. 
Luc2 gene was integrated into a pLenti6.3N5-DEST destination vector using Gateway® 
technology. Then a lentiviral stock was produced co-transfecting the pLenti-Iuc and the viral 
vectors packaging mix into the 293FT cell line, and finally the lentiviral stock was used to 
transduce IA9 and IGROVl cells to obtain stably infected cell lines (lA9-luc and IGROVI-
luc). The evaluation of the luciferase expression is described in the section 4.2.1 of this 
chapter. 
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A portion of IA9-luc and IGROVl-luc cells were also infected with Katushka, to direct 
compare BLI and FLI in the same mice. 
Katushka gene was integrated into a pLenti6.3N5-DEST destination vector, using Gateway® 
technology. Then a lentiviral stock was produced co-transfecting the pLenti-Kat and the viral 
vectors packaging mix into the 293FT cell line, and finally the lentiviral stock was used to 
transduce IA9-luc and IGROVl-luc cells, previously infected with luciferase, to obtain stably 
infected cell lines (lA9-Kat-Iuc and IGROVI-Kat-luc). The evaluation of the Katushka 
expression is described in the section 4.2.2 of this chapter. 
Thus, lA9-luc, IA9-Kat-Iuc, IGROVI-Iuc and IGROVI-Kat-Iuc cells were obtained. 
4.2.1 Evaluation of the luciferase expression and the sensitivity of BLl detection system 
To verify the expression ofluciferase by lA9-luc and IGROVl-luc cells and so as to evaluate 
the sensitivity of BLI detection system, cells were seeded at increasing concentration, ranging 
from lxl06 to 3.l25x104, in a 96-well black plate. Bioluminescence signal was detected 10 
min after the addition of D-Luciferin substrate into the cell medium (Figure 4.1A) with 
eXplore optix MX2. Images analyzed with Optiview software showed that light intensity of 
infected cells, expressed as photon counts, strongly correlated with cell number both in lA9-
luc (Figure 4.1B, r=0.9708, ***p<O.OOOI) and IGROVl-luc (Figure 4.lC, r=0.9973, 
***p<O.OOOl) cells. 
4.2.2 Evaluation of Katushka expression 
Cells were analysed for the expression of Katushka using a F ACST AR (Becton Dickinson, 
Mountain View, CA) in collaboration with Sergio Bemasconi, IRCSS - Istituto di Ricerche 
Farmacologiche Mario Negri, Milan, Italy. 
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The percentage of infected cells were calculated measuring the fluorescence through a 620 nm 
band pass filter after illumination with the 488 nm line of an argon ion laser. The percentage 
of lA9-Kat-luc cells expressing the red fluorescent protein was 97.62%, and the percentage of 
IGROVI-Kat-luc cells was 89.32%. 
To evaluate cell viability and proliferation of the infected cells, growth curve and doubling 
time were determined. 
A significant difference in growth rate and doubling time between lA9-luc and lA9-kat-luc 
cells was observed (Figure 4.2A). The doubling time was 13 hours and 19.6 hours for lA9-luc 
and lA9-Kat-luc, respectively. On the contrary, growth rate was not significantly different 
between IGROVl-luc and IGROVI-Kat-Iuc (Figure 4.2B). The median of the doubling time 
of three independent experiments was 18 hours for both cell line variants. 
The shape of the lA9 Katushka infected cells (Figure 4.20) was different from lA9-luc cells 
(Figure 4.2C), while no differences were observed between IGROVl-luc variants (Figures 
4.2F and 4.2G). 
4.2.3 Comparison between bioluminescence (BLl) andjluorescence imaging (FLI) in vivo 
In order to understand whether the two techniques were useful in vivo, in detecting tumors at 
very early stage (this point was very important, considering that the imaging would be used in 
the following experiments to verify turnor take and to randomize mice before therapy), lA9-
Kat-Iuc and IGROVI-Kat-Iuc cells were transplanted under the bursa of the ovary of nude 
mice. At days 2, 7, 10 and 16 mice were imaged with eXplore Optix MX2 for both 
bioluminescence and fluorescence emission. Briefly, mice were placed on the ventral or 
lateral side onto the warmed stage inside the camera box and then were scanned for 
fluorescence using the 635 nm excitation wavelength pulse laser. After image acquisition 
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mice were injected intraperitoneally with D-Iuciferin substrate and, after 10 minutes, imaged 
for bioluminescence production. 
The images obtained with FLI were not very specific, background was evident in both cell 
lines, especially in correspondence of scars (due to surgery for intraovarian transplant) 
(Figures 4.3A and 4.3B). Only at day 16, a small signal was visible in IGROV1-kat-luc mice 
(Figure 4.3B). 
On the contrary, BLI was very specific: tumor cells were already detected at day 7 for lA9-
Kat-luc and at day 2 for IGROVI-Kat-Iuc, and it was possible to follow tumor growth (the 
photon counts scale increased with time, indicating that also the signal was becoming brighter 
and thus the tumor bigger) and progression. As already observed in vitro, lA9-Kat-luc cell 
growth was very slow. Indeed, photon counts measured by BLI in lA9-Kat-luc tumor only 
reached a peak of 362 photon counts at day 16. On the contrary, IGROVI-Kat-Iuc reached a 
peak of 1.42 x 104 photon counts. 
On the basis of these results, further experiments were carried on using the 1 A9-luc and 
IGROV1-luc cell lines, infected with luciferase only, instead of the luciferase+Katushka-
infected ones. 
4.3 In vitro characterization of VEGFC over-expressing ovarian cancer cell lines 
4.3.1 Establishment of VEG Fe over-expressing eel/lines 
To investigate the role of VEGFC in ovarian carcinoma progression, lA9-luc and IGROVl-
luc cells, which do not express VEGFC, were lentivirally infected to over-express the gene. 
In particular, two different isoforms ofVEGFC with different grade of processing (full-length 
and mature form ofVEGFC) were used. The full-length VEGFC binds only to VEGFR3 and 
can undergo a series of proteolytic processes to become the mature form of VEGFC that has 
higher affinity to VEGFR3 and can also bind to VEGFR2. 
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Briefly, the coding sequence of the full-length VEGFC isoform (VEGFCfl, 1290 bp) or its 
proteolitically activated mature form (VEGFCmf, 490 bp), were integrated into 
pLenti6.3N5-DEST destination vectors, using Gateway® technology. Then lentiviral stocks 
were produced co-transfecting the pLenti-VEGFCfl or pLenti-VEGFCmf and the viral vectors 
packaging mix into the 293FT cell line, and finally the two lentiviral stocks were used to 
transduce lA9-luc and IGROVl-luc cells to obtain stably infected cell lines (lA9-
lucNEGFCfl, lA9-lucNEGFCmf, IGROVl-luc/VEGFCfl and IGROVl-lucNEGFCmf). 
4.3.2 Evaluation of VEGFC expression and release 
The expression of VEGFC was investigated in lA9 and IGROVl cell variants by quantitative 
Real Time PCR using Taqman® technology. 
Gene expression analysis confirmed that VEGFC was undetectable in wild type and luciferase 
infected cells, while a high expression of the gene was observed in the VEGFC-infected cells 
(Figure 4.4). In particular, the relative gene expression calculated as 2·L\CI x 100 was higher in 
VEGFC full length-infected cells (76 and 23 for lA9-lucNEGFCfl and IGROVl-
lucNEGFCfl, respectively) than in cells expressing the mature form of VEGFC (25 and 11 
for lA9-lucNEGFCmfand IGROVI-lucNEGFCmf, respectively). 
Soluble VEGFC was also analyzed by ELISA in serum-free conditioned medium collected 
after 4,24 and 48 hours. VEGFC was not detected in the conditioned media of either lA9-luc 
or IGROVI-Iuc cells (Figure 4.5), confirming the specificity of the assay. The release of 
VEGFC in conditioned medium was time dependent. In particular the amount of VEGFC 
released by lA91ucNEGFCfl and lA9-lucNEGFmf increased with time and reached 7664 
pg/ml and 5005,8 pg/ml, respectively, after 48 hours (Figure 4.5A). Similar increasing trend 
was observed after 48 hours in the conditioned medium of IGROVI-lucIVEGFCfl and 
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IGROVI-lucNEGFCmf, where VEGFC reached 3129 and 728,8 pg/ml, respectively (Figure 
4.5B). 
4.3.3 Biological activity of secreted VEGFC 
The biological activity of VEGFC released by tumor cells was verified as the ability to 
stimulate mouse lymphatic endothelial cell (MELC) migration. Conditioned medium of lA9-
luc cells over-expressing VEGFC induced greater MELC migration than medium conditioned 
by lA9-luc control cells (Figure 4.6A). Increased MELC migration was observed also with 
conditioned medium of IGROVI-lucNEGFCfl and IGROVI-lucNEGFCmf compared to 
medium conditioned by IGROVI-Iuc control cells (Figure 4.68). Conditioned medium of the 
two tumor variants secreting different amounts of VEGFC stimulated MELC migration 
equally, suggesting greater activity of mature VEGFC on cell motility. The specificity of the 
effect was shown on IGROVI-lucNEGFCmf-induced migration by the activity of the 
recombinant VEGFR3IFc chimera. The structure of the human VEGFR3IFlt-4 Fc chimera is a 
fusion between the N-terminus of Flt-4 protein and the C-terminus of the human IgG 1 
antibody, thus the chimera specifically binds to VEGFC and VEGFD, and consequently 
inhibits their activity. It was observed that the chimera inhibited 70% of migration (Figure 
4.6I3), whereas an irrelevant antibody (IgG 1) did not cause any significant inhibition. 
4.3.4 Cell proliferation 
To evaluate whether cell proliferation and doubling time were affected by the infection \Vith 
VEGFC, the growth curve was determined. Briefly, tumor cells were plated in 96-wells 
culture plates in complete medium and after 4, 24, 48, 72 or 96 hours cells were stained with 
crystal violet and the absorbance, proportional to the number of cells, read at 595 nm. 
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Neither daily growth rates nor total growth after 96 hours were significantly different between 
VEGFC wild-type and VEGFC-overexpressing cells (Figure 4.7). The media of the doubling 
time of three independent experiments was 16, 15 and 15.9 hours respectively for lA9-luc, 
lA9-lucNEGFCfl and lA9-lucNEGFmf (Figure 4.7A). IGROVI-luc, IGROV1-
lucNEGFCfl and IGROV1-lucNEGFCmf doubled respectively in 18, 18.4 and 19.7 hours 
(Figure 4.78). 
4.3.5 Autocrine activity: VEGFR3 gene and protein expression 
8esides the paracrine activity of VEGFC through VEGFR3 located on lymphatic endothelial 
cells, the VEGFCNEGFR pathway has been reported to influence tumor progression also 
through autocrine mechanisms (Su, Yang et at. 2006; Kodama, Kitadai et at. 2008) through 
VEGFRs expressed by the turnor cells. 
VEGFR3 and VEGFR2 tumor cell expression was analyzed. lA9 and IGROVl expressing 
VEGFC or not, constitutively expressed comparable levels of VEGFR3 mRNA (Figure 4.8A). 
VEGFR2 mRNA was detectable at very low levels in lA9 variants, while it was not 
detectable in any of the variants of IGROV 1 cells (data not shown). 
The expression level of VEGFR3 on cell surfaces was measured by MiSEP technology. 
VEGFR3 protein was expressed at comparable levels in lA9-luc, lA9-lucNEGFCfl and 
lA9-lucNEGFCmf (Figure 4.88). Comparable levels of VEGFR3 were also measured in 
IGROYl variants (Figure 4.88). 
4.3.6 Autocrine activity: migration 
To demonstrate that VEGFC released by infected cells acted in an autocrine manner, cell 
migration was analysed. Medium conditioned by VEGFC-over-expressing lA9-luc induced 
greater cell migration than medium conditioned by control lA9-luc (Figure 4.9A). Similarly, 
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an increment of cell migration was observed on IGROVl-Iuc cells stimulated with IGROVl-
lucNEGFCfl or IGROVl-IucNEGFCmfconditioned medium compared to control IGROVl-
luc medium (Figure 4.9B), suggesting that VEGFC may directly influence tumor cell 
dissemination through an autocrine mechanism. VEGFCmf conditioned medium stimulated 
tumor cell motility significantly more than VEGFCfl conditioned medium in both cell lines, 
confirming the greater activity of mature VEGFC as chemoattractant. Migration induced by 
the conditioned medium of VEGFC expressing cells, but not of control cells, was completely 
prevented by the VEGFR3/Fc chimera, demonstrating the specificity of the effect (Figures 
4.9C and 4.90). Similarly, cediranib Cl 0 nM), a tyrosine kinase receptor inhibitor of VEGF 
receptors, significantly inhibited lA9-luc migration in response to the conditioned medium of 
lA9-luc/VEGFCmf cells (Figure 4.9E), and IGROVl-Iuc migration in response to the 
conditioned medium of IGROVl-IucNEGFCmf cells (Figure 4.9F), confirming the autocrine 
activity of the VEGFCNEGFR3 pathway on tumor cell motility and suggesting that the 
compound might potentially affect VEGFC-induced tumor dissemination also by directly 
acting on the tumor cells. 
4.4 In vivo characterization ofVEGFC over-expressing ovarian cancer cell lines 
Having demonstrated that VEGFC has both paracrine and autocrine activities on lymphatic 
endothelial cell and tumor cell migration, the effect of the overexpression of VEGFC was 
investigated in vivo, comparing the behavior of wild type tumors to turnors infected with 
VEGFCfl or VEGFCmf. 
4.4.1 Tumor growth and progression 
The three lA9 tumor variants (lA9-luc, lA9-lucNEGFCfl and lA9-lucNEGFCmt) were 
injected orthotopically under the bursa of the ovary of nude mice and turnor growth followed 
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by BLI. Turnor growth was more rapid in lA9-lucNEGFCrnfthan lA9-luc control turnors at 
day 30, although not significantly (Figure 4.1 OA). 
IGROV1-luc over-expressing VEGFC, either the proform or its proteolytically activated 
form, grew faster than control turnors, when injected othotopically into the ovary of 
immunodeficient mice. Twenty-four and twenty-eight days after turnor cell injection, mice 
bearing IGROVI-lucNEGFCrnfand IGROV1-lucNEGFCfl, respectively, had a significantly 
higher turnor burden than mice with the respective control turnors (Figure 4.1 OB). 
Differences in turnor burden did not reflect survival of mice bearing luciferase or VEGFC 
over-expressing cells. Indeed, the MST of lA9-luc, lA9-lucNEGFCfl and lA9-
lucNEGFCrnf-bearing mice were 29, 23.5 and 30 days, respectively (Figure 4.lOC). MST of 
mice bearing IGROV1-luc, IGROV1-lucNEGFCfl and IGROV1-lucNEGFCrnfturnors were 
28, 35 and 28 days, respectively (Figure 4.100). 
As differences in tumor growth were more evident in IGROVI-Iuc, we selected IGROV1-luc 
infected variants (instead of lA9-luc) to investigate more deeply the effect of VEGFC over-
expression on this turnor model. 
4.4.2 VEGFC release 
The release of VEGFC into the serum of mice transplanted with IGROV1-luc, IGROV1-
lucNEGFCfl and IGROV1-lucNEGFCmfwas analyzed by ELISA assay. As expected, only 
mice with VEGFC infected cells had detectable VEGFC in their serum (Figure 4.l1A). 
VEGFC levels increased with time in both IGROV1-lucNEGFfl and IGROV1-
lucNEGFCmf-bearing mice and correlated positively with turnor burden expressed as photon 
counts in both IGROV1-luc/VEGFCfl (***p=0.0043, R2=0.9914, Figure 4.118) and 
IGROVI-IucNEGFCmf(***p=0.0004, R2=0.9992, Figure 4.11C) tumors. 
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4.4.3 ~Metastasis and lymphangiogenesis 
Organs of the periotoneal cavity and para-aortic lymph nodes of mice bearing IGROVI-Iuc, 
IGROVI-lucNEGFfl or IGROVI-lucNEGFCmfwere analysed by histopathology. 
Histopathological analysis indicated that the VEGFC-infected variants, particularly the over-
expressing mature VEGFC, metastasized more efficiently to the diaphragm, the 
retroperitoneal space and the contralateral ovary than control cells. Ninety-two percent of 
mice transplanted with IGROVI-IucNEGFCmf presented neoplastic masses to the 
diaphragm, 67% to the retroperitoneal space and 27% to the contralateral ovary (Table 4.1). 
To verify whether tumor metastasis was associated with induction of lymphangiogenesis 
and/or angiogenesis, immunohistochemical staining of primary tumors with anti-LYVE-l and 
anti-C031 antibodies was done on IGROVl-luc and IGROVI-IucNEGFCmf. Lymphatic 
vessels were detected only at the periphery of primary tumors, in the ovarian septa and 
capsule (Figures 4.12A and 4.128). There was no real difference in lymphatic vessel number 
between tumors releasing VEGFC or not. In a few cases LYVE-I stained vessels invaded by 
tumor cells were observed but exclusively in tumors expressing the mature form of VEGFC 
(Figure 4.128 inset). 
C031-positive blood vessels were located inside the primary tumor parenchyma, as well as in 
the ovarian capsule and septa (Figures 4.12C and 4.120). The number of blood vessels was 
higher, though not significantly, in VEGFC-over-expressing turnors (median 6.0, range 4-10) 
than in control tumors (median 3.9, range 3-6). The difference in blood vessel number 
between the tumor variants was not due to any difference in their capability to recruit 
inflammatory cells, since F4-80+1L YVE-l + (a mature macrophage specific antigen) cells 
were present in both variants without noteworthy differences (data not shown). 
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4.5 Summary of results 
The data presented in this chapter can be summarized as follows: 
• Bioluminescent and fluorescent cell lines are established: light intensity strongly 
correlates with cell number. 
• Bioluminescent cell lines are chosen because of more specific signal in vivo. 
• VEGFC over-expressing cells are established. 
• VEGFC is expressed and released in conditioned medium of infected cells. 
• Secreted VEGFC is biologically active and stimulates mouse lymphatic endothelial 
cell migration. 
• VEGFC does not affect cells proliferation in vitro. 
• Soluble VEGFC has autocrine activity: it induces the migration of VEGFR3-
expressing tumor cells. The migration is prevented by VEGFR3/Fc chimera or 
cediranib. 
• VEGFC over-expressing cells grow faster than wild-type cells when transplanted 
orthotopically under the bursa of the ovary of nude mice, without effect in mouse 
survival. 
• VEGFC is released in serum of mice bearing VEGFC over-expressing cells and it 
correlates with tumor burden. 
• Mice transplanted with VEGFCmf cells present increased metastasis in the organs of 
the peritoneal cavity (e.g. diaphragm, retroperitoneal space and contralateral ovary). 
• Lymphangiogenic activity is apparently not present, though presence oftumor cells in 
L YVE-1 stained vessels is observed exclusively in tumors expressing VEGFCmf. 
• Angiogenic activity is present as there is a tendency to develop more intratumoral 
blood vessels (CD31 +) in VEGFC-over-expressing tumors. 
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4.6 Discussion 
Non-invasive optical imaging techniques, such as BLI and FLI, have emerged as important 
tools in biomedical research. 
In this chapter, it was noted that Kathuska was toxic in IA9-Kat-luc cells, as a slower cell 
growth (both in vitro and in vivo) was observed compared to control cells. And also the shape 
of IA9-Kat-luc cells was different from the lA9-luc. Indeed, limits of fluorescent proteins 
that emit in the red orange are the unsuitable subcellular localization and protein-induced 
toxicity, especially if proteins tend to aggregate (Shaner, Steinbach et al. 2005; Shemiakina, 
Ermakova et al. 2012). The same toxicity was not observed in IGROVI-Kat-luc cells. This 
different behavior between IA9-Kat-luc and IGROVI-Kat-Iuc cells could be explained by the 
different amount of Katushka protein expressed by the cells: IA9-Kat-luc cells expressed 
more Katushka (cells were brighter) than IGROVI-Kat-luc. Thus, more integration of 
Katushka gene is reflected in more toxicity for cells. 
VEGFC, the main promoter of lymphangiogenesis, is expressed in a number of tumors and 
has regulatory functions in their progression and dissemination. Whereas some early studies 
reported a role in the invasive phenotype of ovarian carcinoma, its contribution in the 
pathophysiology of ovarian cancer is far from be clear. 
In this chapter it was demonstrated that VEGFC may significantly promote the growth and 
dissemination of ovarian cancer and that an autocrine effect through VEGFR3 on tumor cells 
might be a critical mechanism for this activity. 
The effect of VEGFC in ovarian tumor progression was investigated in a model of ovarian 
cancer cells over-expressing VEGFC growing orthotopicalIy in the mouse ovary. This model 
presents several advantages over subcutaneous or intraperitoneal injection of tumor cells as it 
reproduces the primary site of turnor growth where tumor cells interact with the appropriate 
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microenvironment and reproduces the pattern of dissemination observed in patients. The limit 
of the orthotopic transplant is that is not possible to check tumor take and to follow tumor 
progression, especially for tumors that grow deeply into the peritoneal cavity of mice. Ovarian 
tumor cells stably expressing luciferase overcome this limit enabling to track growth and 
dissemination of ovarian tumors in real time. 
In this chapter it was sho'Wn that VEGFC promotes in vivo tumor growth and metastatic 
spread of ovarian cancer cells to the diaphragm and the retroperitoneal space, the most 
common sites of ovarian tumor dissemination (Sehouli, Senyuva et al. 2009). VEGFC is 
considered to drive the spread of tumor cells to lymph nodes in some tumors, such as breast 
cancer and melanoma (Skobe, Hamberg et al. 2001; Skobe, Hawighorst et al. 2001). 
However, over-expression ofVEGFC in IGROVl-luc ovarian cancer cells was not sufficient 
to induce para-aortic lymph node colonization, suggesting that other factors are involved in 
driving nodal metastasis in this pathology. Accordingly, in human gastric (Kodama, Kitadai et 
al. 2008), lung carcinoma models (He, Kozaki et al. 2002) and human soft-tissue sarcoma 
(Lahat, Lazar et al. 2009), VEGFC was described as not being the only rate-limiting factor for 
metastasis. 
VEGFC detected in serum of mice bearing VEGFC-overexpressing cells correlated with 
tumor burden, supporting also in these models the possible use of VEGFC released in 
biological fluids as an indicator oftumor burden and invasion. 
Although similar amounts of VEGFC were detected in serum of mice, mature VEGFC had a 
greater effect in inducing metastasis. These findings are in agreement with the fact that 
stepwise proteolytic processing of VEGFC proforms generates several VEGFC forms with 
greater activity and affinity towards VEGFR3 (Joukov, Sorsa et al. 1997). The stronger 
biological activity of VEGFC mature form compared to proforms was confirmed by the 
finding that the conditioned medium ofIGROVl-luc infected with mature VEGFC stimulated 
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lymphatic endothelial cell motility as efficiently as the conditioned medium of IGROY I-Iuc 
infected with full-length VEGFC, despite the smaller amounts of mature YEGFC in the 
conditioned medium. The same effect was observed in another cell line, the I A9-luc, where 
lA9-luc/VEGFCmf and lA9-lucNEGFCfl stimulated MELC motility with the same 
efficiency, even ifhigher amount ofVEGFC were released by IA9-luc/YEGFCfl. 
The mechanism by which the mature form of VEGFC increased metastasis in these models 
might depend on autocrine or paracrine VEGFC activities. It was shown that the 
VEGFC/VEGFR3 autocrine loop can potentially enhance ovarian cancer progression. This 
was demonstrated by the autocrine stimulation of cell motility by VEGFC on both IGROY 1-
luc and lA9-luc turn or cells expressing YEGFR3. 
The specificity of YEGFR3IFc chimera for YEGFC blocking motility served as an additional 
confirmation that VEGFC is involved in IGROYI cell motility. 
The expression and role of YEGFR3 in tumor cells has been debated. Some studies restricted 
the expression of VEGFR3 to blood and lymphatic vessels (Petrova, Bono et al. 2008), while 
others showed that YEGFR3 is expressed in a wide variety of malignant cells, including 
melanoma (Mouawad, Spano et al. 2009), prostatic cancer (Kaushal, Mukunyadzi et al. 
2005), non-small cell lung cancer (Arinaga, Noguchi et al. 2003), neuroblstoma (Beierle, Dai 
et at. 2004) and colorectal adenocarcinoma (Witte, Thomas et at. 2002). It is therefore 
apparent that many tumor cells express YEGFR3 and the responses induced by the 
VEGFClVEGFR3 pathway vary with the tumor type. Although YEGFC released by the 
infected IGROVI-Iuc cells was biologically active and stimulated mouse lymphatic 
endothelial cell migration in vitro, it apparently did not have lymphangiogenic activity in the 
ovarian tumor in vivo. It was noted that lymphatic vessel staining in the primary tumor was 
peritumoral rather than intratumoral, as previously described (Fadare, Orejudos et at. 2008), 
with no differences in lymphatic microvessel density between YEGFC-over-expressing and 
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control tumors. However, tumor cells were detected in lymphatics in VEGFC-over-expressing 
tumors only, indicating that lymphatic vessels were somehow activated by VEGFC, favoring 
tumor cell entry. Results from Issa et al. support this, demonstrating that VEGFC promotes 
tumor invasion toward lymphatics by increasing lymphatic secretion of CCL21 which, in turn, 
drives CCR7-dependent chemotactic tumor invasion (lssa, Le et al. 2009). 
VEGFC stimulated the tumor growth rate in vivo, but not tumor cell proliferation in vitro. 
This can be explained by the complex interaction between tumor cells, host cells and the in 
vivo microenvironment. The tendency to develop more intratumoral blood vessels in VEGFC-
overexpressing IGROV1 turnors compared to control tumors indicates that VEGFC-
stimulated angiogenesis might contribute to the enhanced growth of IGROVI-Iuc over-
expressing VEGFC. 
In conclusion, the mature form of VEGFC contributes to ovarian carcinoma progression by 
directly acting on tumor cells, at the same time inducing angiogenesis and lymphatic vessel 
activation. Blocking the VEGFCNEGFR3 pathway might improve the outcome of patients 
with ovarian cancer through direct antitumor activity in addition to anti-lymphangiogenic and 
anti-angiogenic effects (Chapter 5). 
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Figure 4.1 Correlation between cell number and bioluminescence (BL). (A) A 
representative image of infected cells in vitro. lA9-luc and IGROVI-Iuc cells 
were seeded at densities of 1 X 106 to 3.125 X 104 and imaged 10 minutes after 
adding D-Iuciferin. The experiment was repeated twice. (B) Number of lA9-luc 
cells per well plotted against photon counts. Number of cells correlated with 
amount of emitted light (r2=0.9708, ***p<O.OOOI). (C) Number of IGROVl-luc 
cells per well plotted against photon counts. Number of cells correlated with 
amount of emitted light (r2=0.9973, ***p<O.OOOl). 
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Figure 4.2 Behaviour of Katushka-expressing cells. (A-B) Growth curves. 
Pr liferation capacity measured by absorbance at 595 run (Abs595) every 24 
hours. Data are mean of five replicates representative of three experiments. (A) 
I A9-luc (square) and I A9-Kat-luc (diamonds). *p<O.05. (B) IGROVI-Iuc 
( quares) and T R VI-Kat-Iuc (diamonds). (C) Brightfield image of lA9-luc. 
(D- -< ) Brightfield CD) and fluorescence (E) images of I A9-Kat-luc. (F) 
Brightfield image of IGROVI-Iuc. (O-H) Brightfield (G) and fluorescence (H) 
images ofTGR V l-Kat-Iuc. cale bars represent 100 Ilm. 
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Figure 4.3 ompari on between FLI and BLI techniques in vivo. 
Repre entative images of the same mouse transplanted under the bursa of the 
ovary with (A) lA9-Kat-luc or (B) IGROVI-Kat-Iuc and imaged ate day 2, 7, 10 
and 16 for fluorescence and bioluminescent imaging. 
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Figure 4.4 Expression of hVEGFC transcript in lA9 and IGROVl infected 
cells. RT-PCR. hVEGFC mRNA was normalized to HPRTl housekeeping gene: 
6 Ct = Ctlargcl - Ct"PRTI' Data are expressed as 2- Ct x 100 (mean and SO from one 
experiment representative of three). Experiments were run in triplicate. n.d. = not 
detectable. 
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Figure 4.5 Release of soluble VEGFC in lA9-luc and IGROVI-Iuc infected 
cells. ELISi\ analysis. (A) VEGFC (pg/ml) released in the conditioned medium 
of lA9-luc (squares), lA9-lucNEGFCfl (diamonds) and lA9-lucNEGFCmf 
(triangles). Data arc mean of two replicates representative of three experiments. 
(B) VEGFC (pg/ml) released in the conditioned medium of IGROVl-luc 
(squares), IGROVI-lueNEGFCfl (diamonds) and IGROVI-IucNEGFCmf 
(triangles). Data arc mean and SD of two replicates representative of three 
experiments. 
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Figure 4.6 Biological activity of secreted VEGFC. (A) Lymphatic endothelial 
ce ll motility in re ponse to conditioned media of I A9-luc, I A9-luc/VEGFCfl and 
I A9-luc/VE r- mf. Result are the number of migrated cells (means and 0 of 
at lea t three values from one experiment representati ve of two). ** p<O.O I , 
*** p<O.OOI. (B) Lymphatic endothelial cell motility in response to cond itioned 
media of I R V I-Iuc, I R V \-luc/VEGFC n and (GROV 1-luc/VEGFCmf, 
with or wi thout V ~ Gr-R3/Fc chimera or irrelevant antibody (IgG\). Results are 
the number of migrated ce ll s (means and SO of at least three values from one 
experim nt repre entative of two). *p<O.OS. 
99 
A 
~aoo 
on 
c-
V'; 
~ 
~ 
1000 
Hours 
B 
~ooo 
1500 
V'; 
... 
". 1000 ~ 
~ 
~Oo 
Hours 
Figure 4.7 VEGFC-infccted cells proliferation. Growth curves. Proliferation 
capacity measured by absorbance at 595 nm (Ahs595) every 24 hours. (A) IA9-
luc (squares), IA9-lucNEGFCfl (diamonds) and IA9-lucNEGFCmf (triangles). 
Data are mean of five replicates representative of three experiments. (B) 
IGROVI-Iuc (squares), IGROVI-lucNEGFCfl (diamonds) and IGROV}-
luc/VEGFCmf(trianglcs). Data are mean of five replicates representative of three 
experiments. 
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Figure 4.8 Expre sion of VEGFR3 transcript in infected cells. YEGFR3 
cxprc i n wa ana lyzcd in each IA9 and IGROYI-infected variant in vitro. (A) 
Rl-P R. YE foR3 mR A was normalized to the HPRTI housekeeping gene: 
t = t targct - tllPRTI and expressed as 2-t .ct x 1000 (mean and SO of three 
rcplicatcs from onc cxperiment representative of three). (B) YEGFR3 expression 
on the cell surface was analyzed by Multiplex in situ pitope Profiling (MiSEP) 
and expre sed a arbitrary units (mean and SO of two values). 
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Fi Jure 4.9 Autocrine activity of VEGFC. (A) Effect of conditioned medium of 
J A9-luc I A9-lucN fl and 1 A9-1ucNEGFCmf on lA9-luc cell motility. (B) 
ffect of c nditioned medium of IGROVI-Iuc, IGROVl-lucNEGFCfl and 
r R V l-lucN mf on IGROVI-Iuc cell motility. * p<0.05, **p<O.Ol. (C-
) V R31 c chimera (10 )lg/mL) was added to lA9-luc cells together with 
conditi ned medium of IA9-luc (white) or lA9-luc/VEGFCmf (black, C) or to 
1 R V I-luc cells together with conditioned medium of JGROVl-luc (white) or 
r R V l-luc/V F mf (black, D). Results are the number of migrated cells 
(mean and 0 of at lea t three values from one experiment representative of 
two). * p<0.05 **p<O.Ol. ( -F) Effect of cediranib (10 nM) on lA9-luc (E) or 
I R V I-luc (F) migration induced by conditioned medium of lA9-
lucN mf ( ) or I RV] -luc/VEGFCmf (F). Results are expressed as the 102 
migrated cells as a percentage of controls (vehicle treated cells). * p<O.OS. 
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Figure 4.12 Lymphatic and blood vasculature in IGROV1 tumors over-
c prc ing V j F . I ROY l -Iuc variants expressing mature YEGFC or not 
were implanted in the ovary of immunodeficient mice. (A-B) LYVE-l 
immun taining revealed lymphatic vessels at the periphery of primary tumors, 
and in the epta and cap ule of the ovary. Tumor cells (8 inset) were observed in 
lymphatic ve el of tumor over-expressing YEGFC. CC-D) CD31 
immun tain ing r vealed blood vessels inside the tumor parenchyma and the in 
varian cap ule and epta . cale bars represent 200 Ilm. 
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0/6 
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0/12 
116 (17%) 
0/11 
3111 (27%) 
3/6 (50%) 116 (17%) 
5/12 (42%) 7/12 (58%) 
11112 (92%) 8112 (67%) 
Table 4.1 Metastatic behaviour of IGROVI-Iuc cells expressing VEGFC. 
IGROV1-luc, IGROV1-lucNEGFCfl expressing full-length VEGFC or IGROV1-
lucNEGFCmf expressing the mature form were transplanted orthotopically in the 
ovary of nude mice. Histopathological analysis of para-aortic lymph nodes, 
contralateral ovary, diaphragm and retroperitoneal space was done at killing. Data 
are the number (and percentage) of mice with metastasis over total mice. 
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5.1 Introduction and goals 
In the previous chapters it was sho\\ITI that VEGFC released in serum and ascites of nude mice 
correlated with tumor burden and VEGFCmf over-expression induced increased metastasis to 
diaphragm and retroperitoneal space. Furthermore it was demonstrated that VEGFC not only 
has a paracrine activity on lymphatic endothelial cells, but it has also an autocrine effect on 
the tumor cells. Thus, it was interesting to evaluate the therapeutic potential of the blockade of 
VEGFC/VEGFR3 pathway. For this purpose, since specific inhibitors for VEGFR3 in vivo 
were not available, cediranib, a VEGF receptor tyrosine kinase inhibitor, effective in blocking 
VEGFR3 and VEGFR2 and preventing the formation of lymphatic metastasis was used 
(Padera, Kuo et af. 2008). 
Aims of this chapter are: 
• To evaluate the efficacy of cediranib on in vivo IGROVl-lucIVEGFCmf growth, 
metastasis and survival. 
• To evaluate the efficacy of cediranib on the survival of patient-derived human ovarian 
carcinoma xenografts. 
• To evaluate the efficacy of cediranib in combination with chemotherapy, reproducing 
the ongoing ICON 6 clinical trial. 
Clinically relevant doscs were uscd throughout these studies. 
The work presented is part of a manuscript in preparation. 
5.2 I~csponse to Cediranib of IGROVI-Iuc over-expressing VEGFC 
The efficacy of ccdiranib on tumor progression, survival and invasion induced by VEGFC 
was tcstcd on the IGROVI-Iuc (control variant) and IGROVI-IucNEGFCmf intraovarian 
orthotopic models. IGROVl-luc xenograft allowed us to observe the activity of the 
compound independently from VEGFC (background activity), while the VEGFC-
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overexpressing xenograft pennitted us to focus on the inhibition of the VEGFCNEGFR3 
pathway. 
5.2.1 Tumor progression and survival 
IGROVI-lucNEGFCmf and IGROVI-Iuc cells were transplanted under the bursa of the 
ovary of immunodeficient mice. On day 7 mice were randomized in two groups with the aid 
of BLI on the basis of photon counts. One group (13 mice/group) received cediranib 6 mglkg, 
per os (p.o.), every day for 3 weeks (Qlx21); the control group received vehicle, at the same 
schedule. Mice were monitored by BLI, and at day 28, 24 hours after the end of the 
treatments,S mice per group where sacrificed, in order to analyze the early metastasis pattern 
by histology. Metastasis analysis will be described in section 5.2.2 of this chapter. 
Cediranib was effective on tumor progression of IGROVI-lucNEGFCmf bearing mice. At 
the end of the treatment (day 28) photon counts were 95.5% lower in mice treated with 
cediranib than in vehicle-treated mice (Figure 5.IA and 5.1C, **p<O.OI). Survival reflected 
the progression of the turn or in the peritoneal cavity (Figure 5.1 E): vehicle-treated mice 
rapidly developed tumors and had a median survival time (MST) of 33.5 days; cediranib 
significantly prolonged survival (MST 45 days, ILS 34%, **p<O.005). 
Similarly, cediranib inhibited tumor gro\\th in IGROVI-Iuc bearing mice (Figures 5.1 Band 
5.1 D). However, at day 28 the effect was less pronounced compared to IGROVI-
lucNEGFCmf (58% of reduction compared to vehicle-treated mice, *p<O.05). The effect on 
mice survival (Figure 5.1 F) was comparable to the one observed on VEGFC over-expressing 
cells, with a significant increment of life span (ILS 35%, *p<O.05; MST vehicle 32.5 days, 
MST Ced 44 days). 
5.2.2 Metastasis 
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Five mice per group were sacrificed and necropsied at day 28, at the end of treatment for 
interim analysis. 
Histopathological analysis confinned that the VEGFCmf-infected cells metastasized more 
efficiently to the diaphragm than control cells, with almost all mice presenting neoplastic 
masses (Table 5.1). Interestingly, cediranib affected only metastasis fonned by IGROV1-
lucNEGFCmf and not by IGROV1-luc: only 60% of IGROV1-lucNEGFCmftransplanted 
mice treated with cediranib showed neoplastic masses (Table 5.1). On the contrary, 50% of 
both cediranib treated and untreated mice transplanted with IGROV1-luc presented metastasis 
to the diaphragm (Table 5.1). 
Furthennore, 40% of mice bearing the IGROVI-IucNEGFCmfpresented with ascites (Table 
5.1), while ascites was not present in mice transplanted with the wild-type cells. Cediranib 
was able to inhibit the fonnation of ascites, as none of cediranib-trated IGROVI-
lucNEGFCmf-bearing mice presented ascites (Table 5.1). 
5.2.3 Soluble VEGFC 
In the previous chapter, section 4.4.2, it was demonstrated that VEGFC released in serum of 
IGROVI-lucNEGFCmfbearing mice correlated with turnor burden, thus pointing to VEGFC 
as a possible indicator oftumor burden and invasion. 
The levels of VEGFC released in serum of mice transplanted with IGROV1-lucNEGFCmf 
and treated with vehicle or cediranib (described in section 5.2.1 of this chapter) were analysed 
by ELlSA. 
As expected, the amount of VEGFC detected in the serum of mice of the two groups at 
randomization (day 7) were comparable (Figure 5.2A). At day 28, vehicle-treated mice 
reached 790 pg/ml ofVEGFC, while the levels ofVEGFC from mice of the cediranib group 
were significantly lower (227 pg/ml, **p<O.OI, Figure 5.2A), confinning that VEGFC 
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correlated positively with tumor burden both in vehicle (R2=O.8863, Figure 5.2B) and in 
cediranib-treated mice (p=O.0063, R2=O.9873, Figure 5.2C). 
5.2.4 VEGFRs as biomarkers oftumor burden and response 
The analysis of soluble VEGF receptors (host-derived) released in biological fluids, that could 
be associated to or predict the response to antiangiogenic drugs in mice with patient-derived 
human ovarian xenografts, was carried out. 
Firstly, the presence of soluble VEGFRs was analyzed in serum of mice bearing IGROV-luc 
variants by luminex Milliplex® MAP kit. Soluble VEGFR1 was detected in the serum of 
mice and its levels increased with time after tumor transplant (Figure 5.3A). In particular, it 
was observed that soluble VEGFR1 positively correlated with tumor burden in both VEGFC 
over-expressing and control tumors (Table 5.2). However, the correlation was significant only 
in IGROV1-luc over-expressing VEGFC. On the contrary, in both VEGFC over-expressing 
and control tumors, soluble VEGFR2 (Figure 5.3B) and soluble VEGFR3 (Figure 5.3C) 
decreases with time and they significantly inversely correlated with tumor burden (Table 5.2). 
No differences in soluble VEGFR2 and VEGFR3 were observed among the three IGROV1-
luc variants. 
To test whether VEGFRs were associated with response to cediranib, soluble VEGFRs were 
detected in the serum of mice transplanted with IGROV-luc or IGROV-lucNEGFCmf and 
treated with vehicle or cediranib (section 5.2.1 of this chapter). As observed above, mice 
transplanted with IGROV1-lucNEGFCmf and treated with vehicle showed increasing level 
of soluble VEGFRl (Figure 5.4A), that positively and significantly correlated with tumor 
burden (Table 5.3). On the contrary soluble VEGFR2 decreased with time (Figure 5.4C) and 
inversely correlated with tumor burden (Table 5.3). Soluble VEGFR3 had a decreasing trend 
(Figure 5.4E) and showed an inverse correlation with tumor burden (Table 5.3). 
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As shown above in section 5.2.1, tumor burden, expressed as photon counts, was lower in 
IGROVI-lucNEGFCmf bearing mice treated with cediranib than vehicle (Figure 5.IC). 
Analyzing soluble VEGFRs, it was observed that cediranib-treated mice had significantly 
lower amounts of soluble VEGFRI than vehicles (Figure 5.4A). Similarly, the decrease of 
soluble VEGFR2 was slower in mice treated with cediranib than with vehicle (Figure 5.4C). 
Soluble VEGFR3 seemed to decrease in the same way as in vehicle-treated mice (Figure 
5.4E). Positive correlation between tumor burden and soluble VEGFRI and inverse 
correlation between tumor burden and soluble VEGFR2 or soluble VEGFR3 were observed 
(Table 5.3). 
Similar results were obtained also in the IGROVI-Iuc bearing mice treated with cediranib 
(Figures 5.48, 5.40, 5.4F and Table 5.3). 
5.3 Response to cediranib of patient-derived xenografts 
The efficacy of cediranib was investigated on a panel of patient-derived ovarian cancer 
xenografts (HOC8, HOC 10, HOC22 and HOC79), described in chapter 3, section 3.2.1. As 
described before, all the four tumor xenografts released soluble VEGFC both in ascites and 
scrum, with lower amount of VEGFC detected in the ascites of HOC79 xenograft (Figure 
3.1 ). 
As we have demonstrated that VEGFC acts in paracrine and autocrine fashion in the process 
of tumor progression and metastasis, patient-derived xenografts were characterized for the 
expression ofVEGFR2 and VEGFR3 transcripts by Real-Time PCR. 
VEGFR2 mRNA was expressed in 3 out of 4 xenografts: HOC8 showed the higher 
expression, while VEGFR2 was undetectable in HOC79 (Figure 5.5A). 
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VEGFRJ transcript was detectable in all the xenografi:s, with higher levels for HOC22 and 
lower levels for HOC8 xenografts (Figure 5.58). The expression of VEGFR3 protein was 
confirmed by immunohistochemistry (Figure 5.6). 
The presence of both VEGFR2 and VEGFR3 suggested that VEGFC can act also through an 
autocrine mechanism in these models. 
Then, the efficacy of cediranib was tested. Immunodeficient mice bearing human ovarian 
xenografts were randomized (1 0 mice/group) on day considered Y4 of the median survival 
time for each model (advanced tumor), on the basis of representative mice with confirmed 
tumor burden in the peritoneal cavity. Cediranib was administered per os (p.o.) at a dose of 3 
mglkg once a day for 3 weeks (Q 1 x2I). Vehicle treatment was administered following the 
same schedule of the active compound. 
Cediranib significantly prolonged the survival of mice transplanted with HOC8 and HOCIO 
xenografts, that released comparable levels of VEGFC and also expressed both VEGFR2 and 
VEGFR3 (1I0e8, vehicle, MST 32 days, Ced, MST 44.5 days, ILS 39%, Figure 5.7A; 
1I0C 1 0, vehicle, MST 114.5 days, Ced, MST 142.5 days, ILS 62%, Figure 5.78). 
Interestingly, cediranib showed a stronger effect in the HOC22 model, that released 
comparable amount of VEGFC than HOC8 and HOC 10, but expressed the highest amount of 
VEGFR3 (vehicle, MST 20 days, Ced MST 37 days, ILS 85%, Figure 5.7C). 
On the other hand, cediranib showed a minimal effect on survival of mice transplanted with 
IIOC79 xenograft, that expressed the lowest levels of VEGFC, did not express VEGFR2 and 
express low amount of VEGFR3 (Vehicle, MST 22 days, Ced, MST 26 days, ILS 18%, 
Figure 5.7D). 
5.4. Maintenance therapy on HOeS xenograft 
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Maintenance schedule for anti angiogenic therapy is becoming an issue in current clinical 
trials. Since one of the anns of the ICON6 trial (a phase III clinical trial evaluating the 
combination of chemotherapy plus cediranib in women with platinum-sensitive relapsed 
ovarian cancer) contemplated cediranib maintenance (Raja, Griffin et al. 2011), cediranib was 
administered in maintenance therapy on HOC8 model and the efficacy on tumor survival was 
analyzed. 
This model was chosen because it was well described for correlation of VEGFC and turn or 
burden (chapter 3, section 3.2.1) and lymph nodes invasion (chapter 3, section 3.2.2). 
Furthennore it was sensitive to cediranb given daily for 21 days (section 5.3 of this chapter). 
Nude mice bearing HOC8 were randomized on day seven (ten mice/group), on the basis of 
representative mice with continned tumor burden in the peritoneal cavity, and dosed once-
daily orally with cediranib (3 mglkg) either for twenty-one days or until survival (treatment 
was stopped at day 108, when only 3 mice were alive). Control mice were treated with 
vehicle, following the same schedule and route of active compound, until survival. Detailed 
schedule of the trial is shown in Figure 5.8A. 
As already described in section 5.3 of this chapter, cediranib given for twenty-one days 
significantly increased survival of mice bearing HOC8 tumor xenograft (vehicle, MST 32 
days, Ced, MST 44.5 days, ILS 39%, Figure 5.88). An added benefit of taking cediranib for 
a longer time was observed. Maintenance treatment further prolonged mice survival compared 
to cediranib interrupted after three weeks (Ced7Ced, MST 79 days, ILS 147% vs vehicle, 
."p<O.OOOI, ILS 77.5% vs Ced, #p<O.OOOl, Figure 5.88). 
5.5 Combination therapy: chemotherapy plus cediranib on HOC8 model 
5.5.1 Paclitaxellcisplatin and cediranib induction versus maintenance regimen 
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The effect of cediranib added to PTX +DDP, the standard chemotherapeutics used for ovarian 
carcinoma patients, was tested in the HOC8 model. It was investigated whether cediranib 
enhanced tumor response to chemotherapy. Focusing on the problem of antiangiogenic 
therapy duration, the triple combination of PTX+DDP+Ced was compared with the triple 
combination with maintenance of cediranib (PTX+DDP+Ced7Ced90). This trial reproduces 
the arms ofICON6 clinical trial (Raja, Griffin et al. 2011). 
Briefly, nude mice bearing HOC8 were randomized (ten mice/group) on day 7, on the basis of 
representative mice with confirmed tumor burden in the peritoneal cavity, and treated with 
PTX +DDP as single agent or in combination regimens with cediranib. Detailed schedules of 
the trial are shown in Figure 5.9A. 
At the doses and schedules used, PTX+DDP significantly increased survival (vehicle, MST 
33 days, PTX+DDP, MST 170 days, ILS 415%, 4/10 turnor-free mice on day 180, Figure 
5.9B). Survival was further increased with the addition of cediranib (21 administrations) to 
the chemotherapy (PTX+DDP+Ced), with 6/10 tumor-free mice on day 180 (MST not 
evaluable). Maintaining the treatment with cediranib until day 90 (PTX+DDP+Ced7Ced90) 
equally prolonged the survival with 7/9 tumor-free mice on day 180 (MST not evaluable, 
Figure 5.9B; 1 mouse was excluded from the study because it developed a strain-related 
lymphoma on day 173). As the triple combination (PTX+DDP+Ced) was already very 
effective, no significant differences with cediranib maintenance were observed. 
5.5.2 Cediranib concomitantly or after induction with chemotherapy 
Finally, it was investigated whether it was advantageous to give cediranib concomitantly with 
chemotherapy or sufficient to start the treatment after induction with chemotherapy, in order 
to reduce the stress and discomfort of patients, while maintaining the efficacy of the therapy. 
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Cediranib administered as monotherapy starting from day 22 and maintained until day 90 
(7Ced90) significantly prolonged the survival (MST 103 days, ILS 212%), suggesting that 
this TKRI is effective as monotherapy also on advanced tumor. 
The survival of the group treated with chemotherapy and subsequently with cediranib 
(PTX+DDP~Ced90) was significantly prolonged (MST 122 days, 3/8 tumor-free mice on 
day 180, ILS 270% vs vehicle, ***p<O.OOOI, ILS 18% vs 7Ced90, ***p=0.0002, Figure 
5.10B), although an increment of survival was not observed in respect to chemotherapy alone 
(PTX +DDP, MST 170 days, ILS 415%, 4/10 turnor-free mice on day 180, Figure 5. lOB). 
These data suggested that cediranib administered as monotherapy is very effective on 
advanced tumors; on the other hand the compound administered after chemotherapy is not 
better than chemotherapy alone (PTX+DDP). 
5.6 Summary of results 
The results presented in this chapter can be summarized as follows: 
• Cediranib inhibits tumor growth of both IGROVI-Iuc and IGROVI-lucNEGFmf 
turnors. 
• The effect of cediranib is more pronounced on VEGFC over-expressing tumors. 
• Cediranib is effective in reducing diaphragm metastasis-VEGFC dependent and 
ascites formation. 
• The levels of VEGFC are reduced in cediranib-treated mice compared to controls: 
VEGFC levels correlated with tumor burden (photon counts) in cediranib treated-
mIce. 
• Soluble VEGFRI positively correlates with tumor burden in both IGROVI-
lucNEGFCrnfand IGROVI-Iuc and in both vehicle and cediranib-treated mice. 
• Soluble VEGFR2 and VEGFR3 inversely correlate with tumor burden. 
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• Cediranib is effective on the survival of all the four patient-derived ovarian cancer 
xenografts analyzed. 
• Maintenance regimen of cediranib further increases the survival ofHOC8 xenograft. 
• Cediranib combined with chemotherapy (PTX +DDP) significantly increases the 
survival compared to monotherapies. 
• Cediranib as montherapy is effective on advanced HOC8 tumors. 
5.7 Discussion 
VEGFC and VEGFR3 are interesting novel targets for tumor therapy (Sapo, Anttila et at. 
2012). 
The results of VEGFR3 expression in ovarian turnor cells suggest that agents that interfere 
with the VEGFCNEGFRs axis would have a dual effect on tumor growth and invasion, by 
directly targeting the tumor cells and by inhibiting lymphatic activation and blood vessel 
formation. To confirm this hypothesis, the TKRI cediranib, which inhibits VEGFR3 but also 
VEGFRl, VEGFR2 and c-kit was used. The use ofcediranib was due to the lack of inhibitors 
selective for VEGFR3. 
However, it cannot be ruled out that the activity of cediranib against VEGFR1, VEGFR2 and 
c-Kit contributed to the etTect. 
The results described in this chapter confirmed that VEGFC enhances diaphragm invasion 
and induces ascites production. It cannot be excluded that the inhibition of tumor 
dissemination is secondary to the effect of cediranib on primary tumor growth. On the other 
hand, cediranib efficacy in counteracting these processes only in VEGFC over-expressing 
tumors suggested the specificity of the inhibition of VEGFC. Nevertheless, its significant 
effect on VEGFC-stimulated IGROV1-luc migration in vitro indicates that VEGFR3 present 
on ovarian turnor cells might otTer an effective therapeutic target for ovarian carcinoma. 
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One interesting point of this study was the search of predictive biomarkers of treatment 
response. 
In particular, VEGFC expression was associated with a better response to cediranib. Indeed, 
greater inhibition of turnor burden was observed in IGROVl-luc over-expressing VEGFC-
bearing mice, and cediranib was more effective in patient-derived ovarian carcinoma 
xenografts releasing VEGFC in serum and ascites. 
Furthennore, HOC xenografts that differentially express VEGFR3 and VEGFR2 showed 
different response to cediranib. It was shown that cediranib was more effective on tumor 
expressing VEGFR3. 
The different expression levels of VEGFR3 and VEGFR2 in HOC xenografts supported 
VEGFC autocrine activity observed in vitro in IGROVl and tA9 cells (Chapter 4). In 
addition, the presence of both VEGFC autocrine and paracrine activity, suggest an increased 
efficacy of compounds targeting the VEGFCNEGFR3 pathway. 
The effect of VEGFC on VEGFR2 must be taken into account, as 3 out of 4 xenografts used 
express VEGFR2 in addition to VEGFR3 and the mature fonn of VEGFC can exert 
angiogenic activity through VEGFR2 (Witzenbichler, Asahara et al. 1998; Kodama, Kitadai 
et al. 2008) Thus, the effect of cediranib observed in the xenografts might also be due by 
inhibition of VEGFCNEGFR2 pathway on both endothelial cells (antiangiogenic activity) 
and also tumor cells themselves (autocrine effect). 
Beyond the predictive role as biomarker of response to therapy, VEGFC was confirmed as a 
possible indicator of turnor burden. Indeed, the correlation between tumor burden and 
VEGFC, already described in chapters 3 and 4, was now described to occur in mice treated 
with cediranib. 
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Then, soluble VEGFRs were analysed and the data obtained indicated that soluble VEGFRI 
positively and significantly correlated with tumor burden, while on the contrary soluble 
VEGFR2 and soluble VEGFR3 showed an opposite trend. These correlations were not 
dependent on the over-expression ofVEGFC. All together these results suggested that soluble 
VEGFRl and VEGFR2 are possible candidates as biomarkers of tumor burden, and thus of 
response to therapy. 
The use of soluble VEGFRs as biomarkers of antitumor activity, modulated in response to 
antiangiogenic treatments is far from being clear and the data in the literature are conflicting. 
In some studies, soluble VEGFRs are principally considered pharmacodynamic markers that 
increase after antiangiogenic therapy (Denduluri, Yang et al. 2008; Wong, Buckman et al. 
2010). On the contrary, in other studies VEGFRs are described as decreasing (Deprimo, Bello 
et al. 2007; Rini, Michaelson et al. 2008; Medinger, Esser et al. 2009 ; Hanrahan, Lin et al. 
2010; Pena, Lathia et al. 2010). 
Among antiangiogenic agents, bevacizumab, that is the most studied, demonstrated activity 
on ovarian cancer in a maintenance regimen in terms of both response and progression free 
survival (PFS) (Aghajanian, Finkler et al. 2011; Burger, Brady et al. 2011; Perren, Swart et 
al. 2011; Pujade-Lauraine, Hilpert et al. 2012). Data with cediranib on ovarian cancer are 
lacking. 
Different regimens of cediranib were compared on xenograft models mainly to study the 
relevance of maintenance therapy with this compound. In line with other antiangiogenic 
drugs, cediranib maintenance regimen was more effective than cediranib given for 3 weeks 
(Ced) and significantly prolonged the survival of mice transplanted with HOe8. 
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Surprisingly a strong effect was observed with cediranib single therapy on advanced tumor 
suggesting that cediranib could represent an important therapeutic opportunity for patients 
with advanced turnors for which conventional therapies are not effective (75% patients are 
diagnosed at advanced stage). 
A huge reduction of abdominal distention was observed after cediranib administration, 
suggesting that the efficacy of this TKI on advanced tumor is also due by decrease in ascites 
formation. 
Treatment benefits might be improved combining these treatment strategies with the standard 
first-line treatment for ovarian cancer patients after cytoreductive surgery (Cannistra, Bast et 
al. 2003). Thus, cediranib was combined with PTX +DDP in the HOC8 model. In agreement 
with a recent study (Kendrew, Odedra et al. 2013), the combination was very effective and 
prolonged the survival, resulting in 6/10 tumor-free mice (on day 180). The same efficacy was 
observed when treatment with cediranib was maintained after chemotherapy until day 90. 
This result prompts us to investigate whether cediranib treatment after chemotherapy was 
sufficient to obtain the same outcome. This would be important to reduce the stress and 
discomfort for ovarian cancer patients. Surprisingly, the triple combination of cediranib 
starting after the induction of PTX +DDP, was not advantageous. These results suggest that in 
HOC8 model the concomitance of chemotherapy and cediranib is necessary. Further studies 
on different ovarian tumor xenografts are necessary to confirm these data. 
In conclusion, overall efficacy of cediranib as monotherapy was found in all the xenograft 
models, consistent with the data observed in the two phase II single-agent studies (Hirte, 
Vidal et al. 2008; Matulonis, Berlin et al. 2009). Furthermore these results suggested 10ng-
term treatment of cediranib to improve the efficacy of the compound. These findings on the 
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combination of cediranib and chemotherapy showed the efficacy of the triple combination, 
anticipating the results ofthe ICON6 trial. 
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Figure 5.1 Effect of cediranib on tumor progression and survival. Nude mice 
were transplanted with IGROV1-luc variants under the bursa of the ovary and 
randomized at day 7 on the basis of photon counts. Cediranib was administered 
every day for 21 days (Qlx21) at the dose of 6 mg/kg, p.o. (A-B) One 
representative mouse bearing IGROVl-luc/VEGFCmf (A) or IGROVl-luc (B) 
treated with vehicle or cediranib (Ced) imaged on day 7 and on day 28. (C-D) 
Mice were monitored by BLI on day 7 (randomization) and day 28 (tumor 
progression) and tumor burden expressed as photon counts. Vehicle = black bars, 
Ced = light-blue bars. n=8 (C) IGROVI-lucNEGFCmf bearing mice. **p<O.Ol. 
(D) Mice transplanted with IGROVl-luc cells. *p<O.OS. (E-F) Effect of cediranib 
on the lifespan of the mice bearing IGROVI-Iuc/VEGFCmf (E, **p<O.OOS) or 
IGROVI-luc (F, *p<O.OS). Vehicle = black lines, Ced = light-blue lines. n=8. 
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Figure S.2 Correlation betwecn tumor burdcn and VEGFC released in serum 
of mice bearing IGROVI-Iuc over-expressing mature form of VEGFC. (A) 
Serum VEGFC levels in vehicle (black bars) and cediranib-treated mice (Iight-
blue bars) at randomization (day 7) and at the end of treatment (day 28). n=4. 
**p<O.Ol. (B-C) Correlation between turnor burden expressed as photon counts 
and VEGFC levels in serum of vehicle (B, R2=O.8863) and cediranib (C, 
p=O.0063 , R2=O.9873) treated mice. n=4. 
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Figure 5.3 Soluble VEGFR receptors in serum of IGROVI-Iuc variants. 
Soluble VEGFRl (A), VEGFR2 (B) and VEGFR3 (C) were detected in the serum 
of IGROVI -Iuc (blue), IGROVI-lucNEGFCfl (pink), IGROVl-luc/VEGFCmf 
(green) bearing mice and healthy mice (yellow). *p<O.05, ** **p<O.OOOl. n=3. 
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Figure 5.4 oluble VEGFR receptor levels in serum of cediranib-treated 
mice. erum of nude mice transplanted with IGROVl-luc/VEGFCmf (A, C, E) 
or JGROV1-luc (B, D, F) was collected and soluble VEGFRl (A-B), VEGFR2 
( -D) and V GFR3 (E-F) were measured. Vehicle = black bars, cediranib = 
light-blue bars. n=3-6. **p<O.005, ****p<O.OOOl. 
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Figure 5.5 Expression of hVEGFR2 and hVEGFR3 in patient-derived 
xcnografts. Iluman VEGFR2 (A) and human VEGFR3 (B) transcripts expression 
was analyzed in the four patient-derived xenografts HOe8, HOC 1 0, HOC22 and 
1I0C79 by Real-Time PCR. Target mRNA was normalized to the human beta-
actin housekeeping gene: .1Ct = C~arget - Ctbeta-actin and expressed as 2-~Ct x 1000 
(mean and SD of three replicates from one experiment representative of three). 
n.d. = not detectable. 
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Figure 5.6 VEGFR3 protein expression in HOeS xenograft. Representative 
immunohistochemical images of HOe8 tumors expressing human VEGFR3. 
Scale bars represents 100 Ilm. 
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Figure 5.7 Antitumor activity of cediranib in a panel of patient-derived 
ovarian carcinoma xenografts. Effect of cediranib on the lifespan of HOC8 (A), 
HOCIO (B), HOC22 (C) and HOC79 (D). Cediranib (light-blue lines) was given 
at the dose of3 mg/kg, p.o., daily for 21 days (Qlx21). Black lines represent mice 
treated with vehicles. The light-blue arrows indicated the days at which cediranib 
was administered. n=10. **p<O.Ol , ***p<O.OOl, ****p<O.OOOl. 
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Figure 5.8 Antitumor activity of cediranib on HOC8 xenograft. (A) Protocol of 
the study: treatment started seven days after intraperitoneal HOC8 transplantation 
in nude mice and given daily by oral gavage. Cediranib was used at the dose of 3 
mg/kg, p.o. , and was given for 21 days (Ced) or continued until day 108 
( ed7Ced). (B) Effect of cediranib on the lifespan of mice bearing HOC8 (n=10, 
*** p<O.OOOl vs vehicle, #p<O.OOO I vs Ced). The light-blue and blue bars 
indicated the time at when Ced and Ced7Ced were administered, respectively. 
This graph is from the same trial of graph in Figure S.7A, referring to the same 
vehicle and Ced. Abbreviation: Ced= cediranib. 
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Figure 5.9 Antitumor activity of paclitaxcl plus cisplatin combined with 
cediranib on HOC8 xenograft. (A) Protocol of the study: treatments started 
seven days after HOC8 transplanted intraperitoneally in nude mice. PTX (10 
mg/kg) + DDP (3 mg/kg) were injected i.v. every seven days for 3 cycles. 
Cediranib (3 mg/kg, p.o.) was stopped after three chemotherapy cycles (day 21, 
Ced), or maintained until day 90 (Ced7Ced90). (B) Effect of PTX+DDP alone or 
in combination with cediranib on the lifespan of mice bearing HOC8 (n= IO). All 
the groups were significantly different from vehicle group (***p<O.OOOI). The 
light-blue and blue bars indicated the time at when Ced and Ced-7Ced90 were 
administered, respectively. The arrows indicated the time at when PTX+DDP was 
given. Abbreviation: Ced= cediranib. 
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Figure 5.10 Antitumor activity of cediranib administered after induction with 
chemotherapy on HOC8 xenograft. (A) Protocol of the study: chemotherapy 
treatments started seven days after HOC8 transplanted intraperitoneally in nude 
mice. PTX (10 mg/kg) + DDP (3 mg/kg) were injected i.v. every seven days for 3 
cycles. Cediranib (3 mg/kg, p.o.) started at day 22, at the end of the three cycles 
of chemotherapy (~Ced90) and continued daily until day 90. (B) Effect of the 
di ffe rent treatments on the lifespan of mice bearing HOC8 (n= lO, ***p<O.OOOI vs 
vehicle and ***p=0.0002 vs PTX+DDP~Ced90). The green bar indicated the 
time at when ~Ced90 was administered. The arrows indicated the time at when 
PTX+DDP was given. This graph is from the same trial of graph in Figure 5.9, 
reffering to the same Vehicle and PTX+DDP. Abbreviation: Ced= cediranib. 
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(GROV) vnrinnt IG ROV 1 -Iuc/VEG Femf IGROVI-Iuc 
Treatment Vehicle Cediranib Vehicle Cediranib 
Primary 5/5 (100%) 5/5 (100%) 5/5 (100%) 5/5 (100%) 
tumor take 
Presence 2/5 (40%) 0/5 0/5 0/5 
of asc ites 
Diaphragm 4/4 (100% ) 3/5 (60%) 2/4 (50%) 2/4 (50 tyo ) 
metastas is 
Tnble 5.] Effect of cedirnnib on ascites and diaphragm metastasis. IGROY 1-
luc or IGROY 1-luc/YEGFCmf were transplanted orthotopically in the ovary of 
nudc micc. At day 28 presence of primary tumor and ascites were verified and 
histopathological analys is of diaphragm was done. Data are the number (and 
percentage) of positive mice over total mice. 
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U;n.OVl \'ariant sVE(;nU sVE(;nU sVE(~FR3 
IGROVI-Iuc 
IGROVI-Iucl 
VEGFCfl 
IGROVI-Iucl 
VEGFCrnf 
Rl p Rl P R2 P 
0.8969 ns 0.9308 0.352 0.9832 0.0084 
0.9353 0.0329 0.97 0.0151 0.9840 0.008 
0.992 0.004 0.9139 0.044 0.9495 0.0256 
Table 5.2 Pearson's correlation between tumor burden and soluble VEGFRs. 
Turnor burden, expressed as photon counts and showed in Figure 4.1 OB, had been 
correlated to soluble VEGFRs detected in the serum of IGROV1-luc, IGROVI-
lucNEGFCfl or IGROVI-lucNEGFCmf-bearing mice (Figure 5.3). VEGFRI 
positively correlated with turnor burden, while VEGFR2 and VEGFR3 showed an 
inverse corrleation with tumor burden. ns = not significant. 
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IGROVI-
Vehicle 0.9162 0.0428 0.9796 0.010 0.9460 0.0274 
luc Cediranib 0.9467 0.0270 0.8938 0.7831 ns ns 
IGROVI- Vehicle 0.9097 0.0462 0.8723 ns 0.8064 ns 
lue/ 
VEGFCmf Cediranib 0.9256 0.0379 0.8864 ns 0.9340 0.0336 
Table 5.3 Pcarson's correlation between tumor burden and soluble VEGFRs. 
Tumor burden, expressed as photon counts and showed in Figure 5.1, had been 
correlated to soluble VEGFRs detected in the serum of IGROVI-lucNEGFCmf 
and IGROVl-luc bearing mice, treated with vehicle or cediranib (Figure 5.4). 
VEGFR 1 positively correlated with tumor burden, while VEGFR2 and VEGFR3 
showed an inverse corrleation with tumor burden. ns = not significant. 
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6.1 Conclusions 
This project was aimed to investigate the role of VEGFC and VEGFR3 in ovarian cancer 
progression, as it is an interesting targetable pathway to inhibit ovarian cancer. 
To this purpose, two different models of human ovarian carcinoma xenografts were described 
in chapter 3. Firstly, a panel of patient-derived ovarian carcinoma xenografts maintaining the 
histopathological and molecular features of ovarian cancer patients was investigated, and 
circulating VEGFC in serum and ascites of human ovarian carcinoma bearing mice 
demonstrated. Furthermore, for one ofthese xenografts, the HOC8, it was shown that VEGFC 
levels correlated with tumor burden and lymph node invasion, suggesting that VEGFC 
released in biological fluids might serve as an indicator of tumor burden and invasion and 
confirming the data obtained in patients (Cheng, Liang et al. 2013). 
The second model was the intraovarian orthotopic xenograft obtained by transplanting human 
ovarian tumor cells (lA9 and IGROV1) under the bursa of the ovary of immunodeficient 
mice. The orthotopic model reproduces the appropriate tumor microenvironment and allows 
the emergence of biological features of cancer progression, angiogenic process, metastatic 
phenotype and therapeutic response to therapies with patterns more similar to those observed 
in human cancer. 
These models were used in the next chapter to study the interaction VEGFCNEGFR3. 
In chapter 4, the behavior ofVEGFC over-expressing ovarian cancer cells was studied. 
It was shown that the VEGFC released in the conditioned medium of both IGROVI-
lucNEGFCmf and lA9-lucNEGFCmf cells is biologically active, as it stimulated lymphatic 
endothelial cell motility. 
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VEGFC is the main promoter of lymphangiogenesis, and it is expressed in a number of 
turnors with regulatory functions in their progression and dissemination. Here it was 
demonstrated that VEGFC promoted in vivo tumor growth and metastatic spread of ovarian 
cancer cells to the diaphragm and the retroperitoneal space of experimental mice, although it 
was not sufficient to induce the colonization of para-aortic lymph node from the intraovarian 
orthotopic growing tumors. VEGFC detected in serum of mice bearing VEGFC-
overexpressing cells correlated with turnor burden, confirming the possible use of VEGFC 
released in biological fluids as an indicator of turn or burden and invasion. 
The increased dissemination in the VEGFC over-expressing xenografts might depend on both 
autocrine and paracrine VEGFC activities. Indeed, it was shown that VEGFC released by 
tumor cells enhanced the autocrine stimulation of cell motility on both IGROVl-luc and lA9-
luc tumor cells expressing VEGFR3; on the contrary, the addition of VEGFR3IFc chimera 
(specifically inhibiting VEGFC) to the conditioned medium of VEGFC over-expressing cells 
blocked the induction of cell motility. These data strongly support the involvement ofVEGFC 
in turnor cell migration and dissemination. 
In conclusion, VEGFC contributes to ovarian carcinoma progression by directly acting on 
tumor cells. Moreover, lymphatic dissemination is primarily observed in those tumors over-
expressing VEG FC. 
Since the involvement of VEGFCNEGFR3 in ovarian cancer progression and dissemination 
offered a promising target for therapy, the therapeutic potential of the blockade of this 
pathway was investigated in chapter 5. 
As there were not VEGFR3 selective inhibitors available, cediranib, a VEGF receptors 
tyrosine kinase inhibitor, effective in blocking VEGFR3 and VEGFR2 and preventing the 
formation of lymphatic metastasis was used (Padera, Kuo et al. 2008). 
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This molecule had a dual effect on turnor growth and invasion, by directly targeting the tumor 
cells and by inhibiting lymphatic vessel activation and blood vessel formation (Heckman, 
Holopainen et al. 2008; Medinger, Esser et al. 2009). 
Cediranib was effective on turnor growth and survival of both VEGFC over-expressing or 
wild-type tumors, but the efficacy in counteracting turnor dissemination was observed only in 
IGROV1-luc over-expressing VEGFC turnors, suggesting relevant role of VEGFC in 
metastasis. The significant effect of cediranib on the in vitro migration of IGROV1-luc cells 
stimulated with conditioned medium from VEGFC over-expressing cells supported this 
conclusion. 
The activity of cediranib was also investigated on the panel of patient-derived ovanan 
carcinoma xenograft:s. These xenografts produced ascites, an important feature of ovarian 
cancer and were heterogeneous in the amounts of VEGFC released in ascites and serum; in 
addition VEGFR3 and VEGFR2 expression varied among the HOC tumors. 
It was shown that cediranib was effective on all the xenografts but it was more effective on 
tumor releasing high VEGFC and expressing VEGFR3, thus supporting the importance of the 
VEGFC/VEGFR3 autocrine loop. 
However it cannot be excluded that the effect of cediranib on ovarian carcinoma xenografts 
might be due to the binding of VEGFC to VEGFR2 that can exert both angiogenic activity 
and autocrine effect. 
Different schedules and regimens of cediranib were tested and cediranib was combined with 
chemotherapy in order to reproduce the on-going ICON6 clinical trial and to answer some 
uncertain issues. 
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It was fIrst demonstrated that maintenance therapy was more effective than the 3 weeks-
treatment in prolonging mice survival. Surprisingly, signifIcant prolongation of survival was 
observed starting the treatment with cediranib (single therapy) on advanced tumors (day 22) 
and maintaining until day 90. This is particularly important, since ovarian cancer is frequently 
diagnosed at advanced stage. Reduction of abdominal distention was observed after cediranib 
administration, suggesting that the efficacy of this TKI on advanced tumors was also due to a 
decrease in ascites and thus also indicating the importance of maintenance treatment to keep 
this process under control. 
It was shown that treatment benefIts were improved combining cediranib with chemotherapy, 
although no signifIcant difference was observed with cediranib stopped (day 27) or 
maintained after chemotherapy (day 90). On the contrary, starting cediranib after 
chemotherapy was not advantageous. 
In conclusion, in this thesis it was extensively demonstrated that VEGFC in serum or ascites 
of ovarian carcinoma bearing mice correlated with turnor progression. To be noted that high 
levels of VEG FC have been reported in ovarian cancer patients. 
Moreover, high VEGFC was detected in mice bearing turnors responsive to cediranib and 
levels correlated with the response. This points to VEGFC as a possible indicator of tumor 
burden. 
6.2 Future directions 
As a result of the research performed in this project, further studies can be proposed which 
would strengthen the promising fIndings seen here. 
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First, as it was demonstrated that cediranib was more effective on human ovarian tumor 
xenografts that released a high amount of VEGFC and had the highest expression of 
VEGFR3, a larger panel of patient-derived human ovarian xenografts will be characterized for 
the production of VEGFC and the expression of VEGF receptors. The response to cediranib 
will be further investigated, in order to find a possible correlation between VEGFCNEGFR3 
expression and the response to therapy. The availability of a "signature" predictive of 
response to cediranib could be useful to stratify patients for therapy. 
Second, ovarian cancers secrete large amounts of VEGFA. VEGFA over-expression is 
frequently described in ovarian cancer patients and is associated with disease progression and 
a worse outcome (Bamberger and Perrett 2002). Our previous data with bevacizumab, the 
humanized antibody directed against VEGF A, showed efficacy in patient-derived ovarian 
cancer xenografts (Oliva, Decio et al. 2012); it would be interesting to "vertically inhibit" the 
antiangiogenic pathway, combining bevacizumab and cediranib. This was indeed 
demonstrated in mice bearing human head and neck tumors (Bozec, Gros et al. 2008) and in 
the A431 human vulval tumour xenograft (Kendrew, Odedra et al. 2013). 
This hypothesis that the double inhibition of VEGFA (bevacizumab) and VEGFCNEGFRs 
(cediranib) could improve the efficacy of anti angiogenic therapies also in ovarian cancer is 
worth exploring. 
Then, the search of biomarkers is important for the future of antiangiogenic therapy. To date, 
reliable biomarkers able to predict the efficacy of these treatments are still far from be 
identified. The need for validated biomarkers to select those patients that most likely would 
benefit from antiangiogenic drugs has become even more critical (Jayson, Hicklin et al. 
2012). 
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On the basis of the results presented in this thesis, VEGFC, soluble VEGFRl and soluble 
VEGFR2 seem to be promising molecules to be investigated for this scope. They will be 
analyzed and validated in a bigger panel of patient-derived ovarian cancer xenografts. 
Another important point related to the search of biomarkers is the involvement of stroma in 
the response to antiangiogenic therapy. Indeed, among the mechanisms involved in evasive 
resistance to angiogenic inhibitors, turnor microenvironment (e.g. hypoxia, revascularization, 
recruitment of pericytes) could be relevant (Bergers and Hanahan 2008; Shojaei and Ferrara 
2008). Thus, the effect of the interaction between turnor and mouse stroma on cediranib 
therapy will be investigated, conscious that the drift of stromal components of these turnor 
xenografts from human to mouse could present a relevant drawback of these models. 
As already discussed in chapter 5, the mature form of VEGFC can bind to and activate also 
VEGFR2. Furthermore, cediranib, not only blocks VEGFR3, but also VEGFR2 and 
VEGFRl. For this reason, the influence of VEGFR2 on the results obtained thus far will be 
investigated. 
Cediranib is an antiangiogenic drug and was described to block VEGFC-induced VEGFR3 
activity and Iymphangiogenesis (Heckman, Hyngstrom et al. 2008). In our models it was 
shown that cediranib is effective in inhibiting tumor growth, metastasis, and ascites formation, 
but we have no data regarding the Iymphangiogenic/antiangiogenic effect of cediranib. 
Treated tumors will be stained for markers of lymphatic (L YVE-1) and blood vessels (CD31), 
in order to investigate the possible reduction of vessels after therapy. 
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Tumor cells were detected in lymphatics in VEGFC-over-expressing tumors only, indicating 
that lymphatic vessels were somehow activated by VEGFC, favoring tumor cell entry. It was 
already demonstrated that VEGFC promotes tumor invasion toward lymphatics by increasing 
lymphatic secretion of CCL21 which, in turn, drives CCR7-dependent chemotactic tumor 
invasion (lssa, Le et al. 2009). Therefore, stain for CCL21 will be performed, in relation to 
tumor invasion. 
Finally, as shown in chapter 5, VEGFR3 expression was analysed by immunohistochemistry 
in HOCS xenograft and in a set of 12 patients (Decio, Taraboletti et al. in press, 2014). 
VEGFR3 was expressed by the majority of neoplastic cells and it was mostly localized in the 
cytoplasmic compartment. To further understand the mechanisms and the role of 
VEGFCNEGFR3 pathway in ovarian cancer metastasis, the possible translocation of 
VEGFC-activated VEGFR3 into the nucleus, where it may activate genes with central role in 
cancer progression, will be investigated. This had already been hypothesized for lung 
adenocarcinoma cells and primary lymphatic endothelial cells (Su, Yen et al. 2007). 
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